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ABSTRACT 
 
 
 Following DNA damage, nuclear p53 induces the expression of PUMA (p53 
upregulated modulator of apoptosis), a BH3-only protein that binds and inhibits the 
anti-apoptotic BCL-2 repertoire, including BCL-xL. Structural investigations of PUMA 
and the BCL-xL⋅PUMA BH3 domain complex by X-ray crystallography and nuclear 
magnetic resonance (NMR) spectroscopy reveal a novel, PUMA-induced, 
domain-swapped dimerization of BCL-xL that requires a π-stacking interaction between 
PUMA W71 and BCL-xL H113. PUMA is an intrinsically disordered protein, but upon 
interaction with BCL-xL, PUMA W71 and the PUMA BH3 domain residues fold into an 
alpha helix and subtly remodel BCL-xL to trigger its dimerization. Wild type PUMA or a 
PUMA mutant incapable of promoting BCL-xL dimerization (PUMA W71A) 
equivalently inhibit the anti-apoptotic BCL-2 repertoire to sensitize for death 
receptor-activated apoptosis, but only wild type PUMA promotes p53-dependent, DNA 
damage-induced apoptosis. Biochemical and cellular data demonstrate that 
PUMA-mediated structural remodeling and dimerization of BCL-xL modulates its 
affinity for cytosolic p53, providing a detailed mechanism of BCL-xL, cytosolic p53, and 
PUMA functional cooperation. Our data suggest that within the BCL-2 family, ligand 
binding-induced, domain-swapped dimerization is a critical control point to increase 
signal transduction complexity within the apoptotic pathways. 
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CHAPTER 1.    INTRODUCTION 
 
 
Apoptosis: The Fundamental Tenets 
 
Apoptosis is a genetically controlled process through which multicellular 
organisms dismantle damaged or superfluous cells (Hengartner et al., 1992). Apoptosis 
has roles in tissue development (Braithwaite et al., 2005), homeostasis, and disease 
(Danial and Korsmeyer, 2004). It is defined by a sequence of molecular and 
morphological changes that result in the labeling, packaging, and elimination of dying 
cells. Cells committed to die via apoptosis following developmental cues, stress, or 
infection are culled by phagocytes to prevent a host inflammatory response. 
“Scrambling” of the plasma membrane occurs resulting in the exposure of phosphatidyl 
serine, which is usually restricted to the cytoplasmic face of the cell membrane, to the 
extracellular environment (Bevers and Williamson, 2010). In vivo, the externalized 
phosphatidyl serine and other induced signals allow recognition by phagocytic cells, 
which engulf apoptotic cells (Fadok et al., 2000; Hanayama et al., 2002; Savill and 
Fadok, 2000). There are two general signaling pathways that trigger apoptosis, the 
extrinsic and mitochondrial apoptotic pathways (Figure 1.1) (Tait and Green, 2010). 
How death signals are transduced to activate caspases (cysteinyl aspartate proteases that 
efficiently coordinate cellular dismantling) differentiate the two pathways. Death-
receptor ligation by death ligands is responsible for the induction of the extrinsic pathway 
(Muppidi et al., 2004). The mitochondrial pathway is activated by various developmental 
cues or cytotoxic insults. 
 
Death-receptor ligation by death ligands is responsible for the induction of the 
extrinsic pathway (Muppidi et al., 2004) (Figure 1.1). For example, tumor necrosis factor 
(TNF) binds to its death receptor, TNFR, which causes the recruitment of adaptor 
molecules the adaptor molecule FAS-associated death domain (FADD). Recruitment of 
caspase-8 by TRADD results in dimerization, interdomain cleavage, and finally 
activation of caspase-8 (Boatright et al., 2003; Oberst et al., 2010). Caspase-8 activation 
subsequently induces activation of downstream effector caspases, caspase-3, -6 or -7. In 
some cell types, the extrinsic pathway collaborates with the mitochondrial pathway via 
caspase-8 cleavage-mediated activation of protein BH3-interacting-domain death agonist 
(BID), a pro-apoptotic BH3-only protein (Kaufmann et al., 2007; Yin et al., 1999). 
Caspase-8 activated BID (C8-BID) is subsequently able to engage the mitochondrial 
apoptotic pathway (Figure 1.1). 
 
The mitochondrial pathway is responsible for most apoptotic cell death in 
vertebrates and is engaged by cellular stresses such as DNA damage, cell cycle defects, 
extracellular matrix detachment, hypoxia, or loss of cell survival factors (Vousden and 
Prives, 2009). This pathway is regulated by complex interactions among the BCL-2 
family proteins (Figure 1.1), which regulate the integrity of the outer mitochondrial 
membrane (OMM) (Green and Evan, 2002). The pivotal event that commits a cell to die 
via the intrinsic apoptotic pathway is mitochondrial outer membrane permeabilization 
(MOMP) (Kluck et al., 1997; Yang et al., 1997). As a result of MOMP, cytochrome c 
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Figure 1.1 Intrinsic and Extrinsic Apoptotic Pathways. 
(A) Intrinsic apoptotic stimuli, such as DNA damage activate B cell lymphoma 2 (BCL-
2) homology 3 (BH3)-only proteins leading to BCL-2-associated X protein (BAX) and 
BCL-2 antagonist or killer (BAK) activation and mitochondrial outer membrane 
permeabilization (MOMP). Anti-apoptotic BCL-2 proteins prevent MOMP by binding 
BH3-only proteins and activated BAX or BAK. Following MOMP, release of various 
proteins promotes caspase activation and apoptosis. Cytochrome c binds apoptotic 
protease-activating factor 1 (APAF1), inducing its oligomerization and thereby forming 
the apoptosome that recruits and activates initiator caspase 9. Caspase 9 cleaves and 
activates executioner caspases, caspase 3 and caspase 7, leading to apoptosis. (B) The 
extrinsic apoptotic pathway is initiated by ligation of death receptors with their cognate 
ligands, leading to the recruitment of adaptor molecules such as FAS-associated death 
domain protein (FADD) and then caspase 8. This results in the dimerization and 
activation of caspase-8, which directly cleaves and activates caspases -3 and -7, leading 
to apoptosis. Crosstalk between the extrinsic and intrinsic pathways occurs through 
caspase 8 cleavage and activation of the BH3-only protein BH3-interacting domain death 
agonist (BID). Reprinted with permission by Macmillan Publishers Ltd: Tait, S.W., and 
Green, D.R. (2010). Mitochondria and cell death: outer membrane permeabilization and 
beyond. Nat Rev Mol Cell Biol 11, 621-632.
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is released from the mitochondrial intermembrane space and induces apoptotic protease 
activating factor 1 (APAF1) oligomerization into a caspase activating platform called the 
apoptosome (Zou et al., 1997). The apoptosome binds and promotes the dimerization and 
activation of initiator caspase-9 (Hao et al., 2005; Pop et al., 2006; Riedl and Salvesen, 
2007), which subsequently activates the executioner caspases-3 and -7 (Li et al., 1997; 
Salvesen and Dixit, 1997; Zou et al., 1997). These executioner caspases are responsible 
for the phenotypic hallmarks of apoptosis, such as chromatin condensation, plasma 
membrane asymmetry, and cellular blebbing (Kerr et al., 1972; Salvesen and Dixit, 
1997). 
 
 
The BCL-2 Family Proteins 
 
The B-cell lymphoma 2 (BCL-2) protein and its relatives are functionally 
classified as either anti-apoptotic or pro-apoptotic. Most cells express an assortment of 
both anti-apoptotic and pro-apoptotic BCL-2 proteins (Table 1.1), and the regulation of 
their interactions dictates cell survival or commitment to apoptosis (Chipuk and Green, 
2008). 
 
Anti-apoptotic BCL-2 proteins contain four BCL-2 homology (BH) domains 
(BH1–4) (Figure 1.2). The anti-apoptotic repertoire is comprised of BCL-2-related gene 
A1 (A1), BCL-2, BCL-2-related gene, long isoform (BCL-xL), BCL-w, and myeloid cell 
leukemia 1 (MCL-1) (Youle and Strasser, 2008). These proteins preserve the integrity of 
the outer mitochondrial membrane (OMM) by directly inhibiting pro-apoptotic BCL-2 
proteins. 
 
The pro-apoptotic BCL-2 members are divided into 2 groups: the multidomain 
effector proteins and the BH3-only proteins (Youle and Strasser, 2008). The multidomain 
effector proteins, BCL-2 antagonist/killer (BAK) and BCL-2-associated X protein 
(BAX), were originally described as being composed of only three BH domains (BH1-3). 
Structure-based alignment of folded BCL-2 family proteins redefined the BH4 domain 
motif and revealed that it is structurally conserved within the N-terminal helix of both 
multidomain effector and anti-apoptotic BCL-2 proteins (Kvansakul et al., 2008) (Figure 
1.2). As their name implies, the BH3-only proteins contain only the BH3 domain (Figure 
1.2) (Youle and Strasser, 2008). 
 
 
Effector Protein Activation 
 
BAK is constitutively anchored to the OMM by its carboxyl-terminal (C-terminal) 
transmembrane helix, whereas BAX exists as an inactive monomer within the cytosol 
(Wei et al., 2000). Following BH3-only protein-induced activation, BAK and BAX form 
homo-oligomers of various sizes which insert into the OMM and promote MOMP and 
ultimately apoptotic cell death (Figure 1.3). BAK and BAX are essential for MOMP and 
induction of the mitochondrial apoptotic pathway, as Bak-/-Bax-/- cells are refractory to 
apoptosis induced by an assortment of death stimuli (Wei et al., 2001). 
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Table 1.1 The BCL-2 Family Proteins. 
 
Anti-apoptotic 
Proteins 
Pro-apoptotic 
Effector Proteins 
Pro-apoptotic 
BH3-only Proteins 
 
A1 
 
BAK 
 
Direct Activators 
 
BCL-2 
 
BAX 
 
BID 
 
BCL-w 
  
BIM 
 
BCL-xL 
  
De-repressor/ 
Sensitizers 
 
MCL-1 
  
BAD 
   
BMF 
   
HRK 
   
Noxa 
 
 
 
 
 
PUMA 
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Figure 1.2 BCL-2 Family Domain Organization. 
Schematic representations of the domain arrangements of the indicated BCL-2 family 
member groups. Grey cylinders represent alpha (α) helices and magenta cylinders 
represent helical transmembrane domains (TM). The BCL-2 homology (BH) domains are 
indicated above each schematic: BH4, BH3, BH1, and BH2 domains are pink, green, 
yellow, and blue, respectively.  
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Figure 1.3 Proposed Model of BAX Activation. 
Soluble BAX interacts with a direct activator and the OMM to promote stable N-terminal 
exposure, and BAX α5, α6, and α9 insert within the OMM. Reprinted with permission by 
Macmillan Publishers Ltd: Chipuk, J.E., Moldoveanu, T., Llambi, F., Parsons, M.J., and 
Green, D.R. (2010). The BCL-2 family reunion. Mol Cell 37, 299-310. 
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Each BH3-only protein has a unique binding profile for the anti-apoptotic 
repertoire (Figure 1.4A). There are two different types of BH3-only proteins. One subset 
interacts only with the anti-apoptotic BCL-2 repertoire and is referred to as ‘‘sensitizer’’ 
and/or ‘‘de-repressor’’ BH3-only proteins. The other subset, “direct activator” BH3-only 
proteins, can directly interact with both the anti-apoptotic BCL-2 repertoire and the pro-
apoptotic effector proteins (Chipuk et al., 2010). The currently known direct activator 
BH3-only proteins include BID and BCL-2-interacting mediator of cell death (BIM). 
These BH3-only proteins directly induce BAK and/or BAX oligomerization and MOMP 
(Chipuk et al., 2010). 
 
 
Sensitization versus De-repression 
 
As discussed above, BID and BIM directly induce effector protein activation and 
function (Kuwana et al., 2002; Wei et al., 2000). The presence of the BH3 domain of 
BH3-only proteins is necessary and sufficient for BH3-only protein function. For 
example, BH3 domain peptides derived from BID and BIM induce BAK and BAX 
oligomerization and pore-forming activity with isolated mitochondria or large unilamellar 
vesicles (LUVs, lipid vesicles that faithfully mimic the OMM) (Kuwana et al., 2005; 
Letai et al., 2002). 
 
BH3-only proteins, such as BAD, BCL-2-interacting killer (BIK), Harakiri 
(HRK), Noxa, and PUMA function not by directly activating BAK or BAX but rather 
mediate BAK and/or BAX activation indirectly by binding the anti-apoptotic repertoire 
(Chen et al., 2005; Chipuk et al., 2008; Kuwana et al., 2005; Letai et al., 2002).  The 
terms ‘‘sensitizer’’ and ‘‘de-repressor’’ are used to indicate the outcomes of interaction 
between BH3-only proteins and anti-apoptotic BCL-2 proteins. These BH3-only proteins 
establish two distinct mechanisms to indirectly promote effector protein activation: 
sensitization and de-repression (Chipuk et al., 2008; Kuwana et al., 2005; Letai et al., 
2002) (Figure 1.4B-C).  
 
Sensitization lowers the pro-apoptotic signaling threshold for BAK and/or BAX 
activation and MOMP but does not directly induce apoptosis (Figure 1.4B). In this 
scenario, anti-apoptotic BCL-2 proteins become saturated with sensitizer BH3-only 
proteins (via formation of anti-apoptotic protein·sensitizer BH3-only protein complexes), 
effectively preventing inhibition of subsequent direct activator BH3-only protein 
signaling and function (Chipuk et al., 2010). For example, if BCL-2 is associated with 
PUMA (which potently inhibits the entire BCL-2 repertoire, any future induction of BIM 
would not be inhibited and MOMP would proceed. In the absence of PUMA, BIM would 
be sequestered and the cell may survive. 
 
In the case of de-repression, a direct activator BH3-only protein is bound by an 
anti-apoptotic BCL-2 protein, and a subsequent BH3-only protein releases the direct 
activator to promote MOMP (Figure 1.4C). For example, reparable cellular stress can 
induce BIM function, but this activity would be blocked by the anti-apoptotic repertoire 
and the cell would survive. If however, a de-repressor BH3-only protein is induces while  
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Figure 1.4 BH3-only Protein Function. 
(A) The anti-apoptotic BCL-2 protein binding profiles for the BH3-only proteins. Anti-
apoptotic proteins are shown within yellow boxes. Solid blue lines indicate inhibitory 
interactions. (B) Sensitizer BH3-only protein function. A sensitizer BH3-only protein 
inhibits the anti-apoptotic BCL-2 repertoire. Following minimal cellular stress, a direct 
activator is induced but cannot be inhibited and MOMP proceeds. (C) De-repressor BH3-
only protein function. A direct activator is sequestered by an anti-apoptotic BCL-2 
protein. Following cellular stress, a de-repressor BH3-only protein is induced and 
competes with the direct activator for binding to the anti-apoptotic repertoire. When the 
direct activator is released, MOMP proceeds. Reprinted with permission by Macmillan 
Publishers Ltd: Chipuk, J.E., Moldoveanu, T., Llambi, F., Parsons, M.J., and Green, D.R. 
(2010). The BCL-2 family reunion. Mol Cell 37, 299-310. 
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the direct activator is sequestered, the latter can be released, allowing for MOMP (Chipuk 
et al., 2010). De-repressor BH3-only proteins release direct activator BH3-only proteins 
via direct competition for the same binding epitope on the various anti-apoptotic proteins 
present within the cell. Thus whether a direct activator BH3-only protein is de-repressed 
depends on what anti-apoptotic proteins are present, the binding affinities for both the 
direct activator and the de-repressor BH3-only protein for these particular anti-apoptotic 
proteins, as well as the relative concentration of the induced/activated de-repressor BH3-
only protein (Certo et al., 2006; Letai et al., 2002).   
 
Studies using Förster resonance energy transfer (FRET) demonstrated that de-
repression and consequential direct activation occur via protein·protein interactions that 
are not readily detected in the absence of membranes (Lovell et al., 2008). For example, 
activated BID (C8-BID) was bound by BCL-xL, and this interaction could be disrupted 
by BAD. C8-BID subsequently interacted directly with BAX and induced subsequent 
BAX oligomerization and LUV permeabilization. In sum, MOMP readily occurs 
following the combined efforts of direct activator and sensitizer/de-repressor BH3-only 
proteins both in vitro (Chipuk et al., 2008) and in vivo (Merino et al., 2009). 
 
 
BH3-only Protein Regulation 
 
The multiplicity and intricate regulation of mammalian BH3-only proteins 
combine to allow these pro-apoptotic proteins to provide exquisite control over apoptosis. 
As such, activated BH3-only proteins act as death signal mediators following a multitude 
of distinct cellular stress scenarios (Chipuk et al., 2010). Transcriptional upregulation is 
one means by which BH3-only protein activation can occur. Noxa and PUMA are 
induced by the tumor suppressor p53 in response to DNA damage (Nakano and Vousden, 
2001; Oda et al., 2000; Yu et al., 2001), and BIM is induced by the class O forkhead box 
transcription factor-3A (FOXO3A) in response to growth-factor deprivation (Dijkers et 
al., 2000) as well as by the CEBP homologous protein (CHOP) transcription factor in 
response to endoplasmic reticulum stress (Puthalakath et al., 2007). Post-translational 
modification is another means for mediating BH3-only protein activation. BAD 
activation ensues following growth-factor deprivation-induced dephosphorylation (Zha et 
al., 1996). As described above, BID is activated by caspase-8-mediated proteolytic 
cleavage (Li et al., 1998; Luo et al., 1998). BIM activation follows its release from the 
dynein motor complex (Puthalakath et al., 1999) or by loss of extracellular signal-
regulated kinase (ERK)-mediated phosphorylation (which targets BIM for ubiquitin-
mediated proteasomal degradation in healthy cells) (Akiyama et al., 2003; Ley et al., 
2005). BMF is activated by release from actin-myosin motor complexes (Puthalakath et 
al., 2001), and BIK is activated by an unknown mechanism in response to inhibition of 
protein synthesis (Shimazu et al., 2007). 
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Structural Biology of the BCL-2 Family Proteins 
 
The BCL-2 family can be divided into two groups based on protein structure: 
folded, globular proteins and intrinsically disordered proteins (IDPs) (Hinds et al., 2007).   
The primary amino acid sequence of IDPs are rich in polar and charged amino acids, 
while the number of hydrophobic amino acids is low enough to limit the presence of a 
hydrophobic core (Dyson and Wright, 2005). In isolation, IDPs lack secondary and 
tertiary structure  (Wang et al., 2011). Rather they exist as a multitude of conformational 
ensembles (Mittag and Forman-Kay, 2007).  All multidomain anti-apoptotic and pro-
apoptotic effector proteins are folded, helical bundle proteins that share a conserved 
BCL-2 core (BC) (Figure 1.5) (Petros et al., 2004b).  
 
With the exception of its conserved BH3 domain, the BH3-only protein BID 
exhibits the lowest degree of primary sequence conservation among the folded BCL-2 
family members. Nonetheless, the solution structure of BID revealed that the BC is in 
fact structurally conserved (Chou et al., 1999). Other BH3-only proteins are intrinsically 
disordered (Hinds et al., 2007), and the BH3 domains fold into α helices upon binding to 
hydrophobic grooves of BCL-2 family proteins. 
 
The BC was first observed in the structure of BCL-xL (Muchmore et al., 1996a) 
and is an approximately 20 kDa globular domain comprised of six amphipathic α helices 
arranged around a pair of central, buried helices. A hydrophobic groove formed by the 
BH1-3 domains is found on one side of the BC. The C-terminal α helix of BAX, BCL-w, 
and probably full-length BCL-xL resides within this hydrophobic groove, whereas the 
groove is solvent exposed in other folded BCL-2 family members that are constitutively 
tethered to the OMM (Figure 1.5). This hydrophobic groove is requisite for 
heterodimerization between the BH3 domains of pro-apoptotic BH3-only proteins and the 
anti-apoptotic BCL-2 repertoire. The BH4 region is structurally defined by the conserved 
α1 helix and stabilizes the BC hydrophobic groove by packing against the remaining 
three BH domains (Figure 1.5).  
 
Examination of the various BC binding grooves reveals a hydrophobic groove of 
variable width lining one side of the BC (Figure 1.5), decorated on either side by distinct 
combinations of aliphatic, aromatic, polar, and charged amino acids. In addition to the 
amino acid sequence of the various BH3-only domains (Figure 1.6), the degree of 
flexibility of the various anti-apoptotic proteins’ BC grooves, the structural differences in 
the BC grooves and the amino acids surrounding them define anti-apoptotic protein 
selectivity for BH3-only proteins (Czabotar et al., 2007; Day et al., 2005; Day et al., 
2008; Denisov et al., 2006; Feng et al., 2007; Herman et al., 2008; Petros et al., 2000; 
Sattler et al., 1997; Smits et al., 2008). 
 
It is clear that the helical BCs of the anti-apoptotic proteins exhibit varying 
degrees of dynamics which dictate their structural transitions upon BH3 domain binding 
(Smits et al., 2008). Comparing the structures of apo BCL-xL and apo MCL-1 with the 
respective BIM-bound structures provides a clear example of the variable dynamics of 
the BC binding groove (Figure 1.7). The most striking structural difference between apo 
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Figure 1.5 Structures of the BCL-2 Family Protein Core. 
Ribbon representation of multidomain anti-apoptotic and pro-apoptotic BCL-2 family 
proteins: BCL-xL (PDB ID:1LXL), MCL-1 (PDB ID:1WSX), BCL-w (PDB ID:1MK3), 
BAK (PDB ID:2IMT), and BAX (PDB ID:1F16). The BH4, BH3, BH1, and BH2 
domains are pink, green, yellow, and blue, respectively. Carboxyl terminal (C-terminal) 
transmembrane (TM) domains are magenta. 
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Figure 1.6 Sequence Alignment of BH3 Domains from BH3-only Proteins. 
Residues completely and partially conserved are colored magenta and yellow, 
respectively. 
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Figure 1.7 Structural Comparison of Apo Anti-apoptotic Proteins Compared 
with the Respective BH3 Domain-bound Forms. 
(A) Overlay of apo BCL-xL (PDB ID:1LXL) and the BCL-xL·BIM complex (PDB 
ID:3FDL). Apo and BIM BH3 domain-bound BCL-xL are green and blue, respectively. 
The BIM BH3 domain is magenta. (B) Overlay of apo MCL-1 (PDB ID: 1WSX) and the 
MCL-1·BIM complex (PDB ID:2PQK). Apo and BIM BH3 domain-bound MCL-1 are 
pink and cyan, respectively. The BIM BH3 domain is yellow. Red dashed circles 
highlight alpha (α) helices three and four in the apo versus BIM BH3 domain-bound 
BCL-xL and MCL-1 structures (A-B). 
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MCL-1 and BCL-xL and the BH3 domain-bound forms is the behavior of helices α3 and 
α4, which flank the groove and provide contact residues for the BH3 domain (Day et al., 
2005). In BCL-xL, α4 undergoes a rotation to alter the α4-α6 helix crossing angle from 
approximately 60° to almost parallel with α6, and the residues of α3 become less ordered 
on binding (Day et al., 2008). These ligand-induced changes in BCL-xL result in ligand-
induced formation of the BH3 domain binding site by exposing residues that are 
otherwise buried in the closed conformation and creating space for the ligand (Figure 
1.7A). In contrast, α3 of MCL-1 remains essentially unperturbed upon ligand binding 
(Figure 1.7B), and while α4 of MCL-1 does undergo a translation to widen the BC 
groove, a larger translation of the α4 helix was observed for BCL-xL binding (Day et al., 
2008). 
 
 
The p53 Tumor Suppressor and Apoptosis 
 
The p53 tumor suppressor protein is arguably the most well-recognized tumor 
suppressor within the literature to date, and has even been dubbed guardian of the 
genome (Lane, 1992) because of its nodal position linking many different pathways that 
safeguard the integrity of genetic information in response to various genotoxic and non-
genotoxic insults (Vogelstein et al., 2000). Loss of normal p53 function via inactivating 
mutations or an increase in p53 negative regulatory proteins is a hallmark of nearly all 
cancers. The tumor suppressor gene TRP53 encodes a transcription factor that regulates 
genes involved in apoptosis, cell cycle control, DNA repair, metabolism, and senescence 
(Vousden and Prives, 2009).  
 
Cells that are insulted by oncogene activation, DNA damage, or other forms of 
stress stabilize the p53 protein by phosphorylation or other post-translational 
modifications (Bullock and Fersht, 2001) (Figure 1.8). Stabilized p53 accumulates in the 
nucleus and activates the expression of numerous pro-apoptotic genes including APAF-1, 
BAX, PIG3, PUMA, Noxa CD95 (Fas), DR5/Killer, p53AIP1, Pidd, and Dram, to name 
only a few (Vousden and Prives, 2009). Silencing each of these genes in model systems 
leads to partial resistance to p53-induced apoptosis. The general view is that these genes 
govern the decision to live or die based on the cell type investigated and the applied death 
stimulus (Vousden and Prives, 2009). 
 
 
PUMA 
 
PUMA is a de-repressor BH3-only protein which collaborates with direct 
activator proteins to efficiently induce MOMP (Chipuk et al., 2008). Apoptotic signals 
trigger p53 levels to build within the nucleus where it serves as a transcription factor, 
rapidly up-regulating the expression of target genes including PUMA. As PUMA protein 
begins to amass within the cytoplasm, it subsequently translocates to the mitochondria 
where it initiates the mitochondrial apoptotic program via either sensitization or de-
repression, described above. There are two isoforms of PUMA, α and β. Importantly, 
both isoforms contain identical BH3 domain sequences, and aside from the sequences  
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Figure 1.8 p53 Regulation. 
In normal cells, p53-dependent transcription of MDM2 promotes p53 degradation. 
Cellular stress, such as oncogene activation, induces p14ARF, which sequesters MDM2. In 
addition, DNA damage and chemotherapeutic agents activate protein kinases, such as 
ATM and ATR, which, through DNA-dependent protein kinase (DNA-PK) and casein 
kinase II (CKII), respectively, phosphorylate the amino terminus of p53 to prevent 
MDM2 binding, and the carboxyl terminus of p53 to increase sequence-specific DNA 
binding. These events increase p53 levels and activate the transcription of p53 target 
genes. p21 and 14-3-3  promote growth arrest at the G1 and G2 DNA-damage 
checkpoints by inhibiting cyclin-dependent protein kinase (CDK) activity; FAS, BAX 
and p53AIP promote apoptosis if repair is not possible; and GADD45 promotes DNA 
repair. Reprinted with permission by Macmillan Publishers Ltd: Bullock, A.N., and 
Fersht, A.R. (2001). Rescuing the function of mutant p53. Nat Rev Cancer 1, 68-76. 
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N-terminal to the BH3 domain, the sequences of the isoforms are identical (Figure 1.9), 
and the kinetics of their upregulation following genotoxic stress are identical (Chipuk et 
al., 2008). 
 
 
Puma Knockout Mice Are Resistant to Apoptosis 
 
Loss of Puma results in resistance to numerous p53-dependent and -independent 
death stimuli in vivo indicating that this protein likely functions in numerous apoptotic 
networks (Jeffers et al., 2003; Villunger et al., 2003). Puma-/- mice were born at the 
expected Mendelian frequency, appeared normal and exhibited proper cellularity of the 
hematopoietic organs (Jeffers et al., 2003). Yet, numerous Puma-/- cell types (e.g., 
thymocytes, pre-B and mature B- and T-cells) were markedly resistant to genotoxic 
stress-induced apoptosis (e.g., γ-irradiation), similar to apoptosis resistance observed in 
Trp53-/- mice (Jeffers et al., 2003). PUMA may also regulate p53-independent pathways 
because CD4+8+ thymocytes derived from Puma-/- animals displayed resistance to 
dexamethasone and staurosporine, two known inducers of p53-independent apoptosis 
(Jeffers et al., 2003). This suggests that PUMA may participate in several death networks 
to sensitize cells to death stimuli that are regulated by diverse pro- and anti-apoptotic 
BCL-2 proteins. 
 
 
Apoptosis and Cancer 
 
Defects in apoptosis play important roles in tumor pathogenesis, allowing 
neoplastic cells to survive beyond their normally intended lifespan, subverting the need 
for exogenous survival factors, providing protection from hypoxia and oxidative stress as 
tumor mass expands, and allowing time for accumulative genetic alterations that 
deregulate cell proliferation, interfere with differentiation, promote angiogenesis, and 
increase cell motility and invasiveness during tumor progression (Reed, 1999). Apoptosis 
defects are recognized as an important complement to proto-oncogene activation, as 
many deregulated oncoproteins that drive cell division also trigger apoptosis (Green and 
Evan, 2002). Similarly, defects in DNA repair and chromosome segregation normally 
trigger apoptosis as a defense mechanism for eradicating genetically unstable cells, 
providing opportunities for selection of progressively aggressive clones (Ionov et al., 
2000). Apoptosis defects also facilitate metastasis by allowing epithelial cells to survive 
in a suspended state with no extracellular matrix attachment (Frisch and Screaton, 2001). 
 
 
PUMA and Cancer 
 
Eμ-myc transgenic mice develop B-cell lymphomas with 100% incidence within 
the first year of life (Egle et al., 2004). This lymphomagenesis is accelerated by loss 
ofp53 or loss of ARF, an important protein which activates expression of p53 due to 
uncontrolled mitogenic signaling by inhibiting MDM2 (Eischen et al., 1999a). 
Consistently, loss of a single copy of Puma drastically accelerates c-myc-induced B-cell 
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Figure 1.9 Comparison of PUMA Alpha and Beta Isoforms. 
Other than the extreme amino- (N-) terminus (residues 1-93 and 1-31 for the alpha and 
beta isoforms, respectively), both isoforms share identical sequences Numbers above 
each schematic represent amino acid numbers for the respective isoforms. The N-termini 
of PUMA alpha and beta are shown as green and magenta boxes, respectively. 
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lymphomagenesis (Labi et al., 2006). When hematopoietic stem cells from Eμ-myc 
transgenic mice infected with a Puma-specific shRNA construct were transferred into 
normal recipients, lymphomas also arose with a drastically reduced latency, and disease 
onset was comparable to that observed in the absence of p53 (Hemann et al., 2004). 
Interestingly, the Eμ-myc lymphomas that carry a Puma-specific shRNA maintained wild 
type p53 status and could undergo cell cycle arrest in response to γ-irradiation (Hemann 
et al., 2004). In contrast, p53 is frequently inactivated or lost in Eμ-myc lymphomas 
(Eischen et al., 1999b), therefore it appears that the pressure to lose p53 is obviated by 
loss of PUMA. Importantly, in a recent landmark study, an enormous collection of human 
cancer samples were screened for somatic copy-number alterations and found PUMA 
deletion to be the most frequently deleted pro-apoptotic BCL-2 family gene (Beroukhim 
et al., 2010). Together, these findings strongly suggest that when cell cycle control is 
deregulated (e.g., by c-myc overexpression), the pro-apoptotic function of p53 is its most 
critical activity in tumor suppression (Labi et al., 2006).  
 
The chromosomal locus 19q13.3, harboring the PUMA gene is frequently lost in 
human gliomas, neuroblastomas, and certain B-cell lymphomas (Mora et al., 2001; 
Shimazaki et al., 2000; Yong et al., 1995). It has also been reported that PUMA 
expression decreases during the development of malignant cutaneous melanoma (Karst et 
al., 2005). In addition, complete silencing of PUMA via epigenetic hypermethylation was 
found in approximately 40 % of primary human Burkitt’s lymphoma (Garrison et al., 
2008). 
 
There is also compelling evidence for the involvement of PUMA in p53-mediated 
renal cell apoptosis during cisplatin-induced nephrotoxicity (Jiang et al., 2006). 
Therapeutically, this finding suggests the possibility of renal protection by blocking p53 
or PUMA during cisplatin treatment. Further, it has also been established that PUMA is 
an essential mediator of cardiomyocyte death in response to Infarction/Reperfusion (I/R) 
(Toth et al., 2006). The study proposes a link between PUMA and I/R-associated 
myocardial dysfunction. On the basis of the marked resistance of PUMA deficient hearts 
to I/R, PUMA holds promise as a potential target for therapeutic intervention (Toth et al., 
2006). 
 
 
BCL-xL and Cancer  
 
The noncompliant nature of cancer cells (e.g. exhibiting oncogene activation, cell 
cycle checkpoint violation, and genomic instability to name but a few transforming 
features) constitutively provokes death signals by engaging the apoptotic program, yet 
still these rogue cells manage to evade cell death. The road to tumorigenesis must, 
therefore, require apoptotic deficiency as a component. In support of this notion, it has 
been established that numerous cancer cell types become addicted to BCL-xL (and other 
anti-apoptotic members of the BCL-2 family) (Certo et al., 2006; Green and Evan, 2002).  
 
Over-expression of BCL-xL occurs in more than half of all cancers (Amundson et 
al., 2000), rendering tumor cells resistant to numerous apoptotic stimuli, including 
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oncogene expression and most cytotoxic anticancer drugs. Indeed, in the study which 
screened somatic copy-number alterations, mentioned above regarding PUMA, found 
BCL-xL amplification to be the most frequently overexpressed BCl-2 family gene 
(Beroukhim et al., 2010). Thus, understanding how BCL-xL functions, and relationships 
between its structural, biophysical, biochemical, and functional properties, is critical for 
understanding the role of BCL-xL in cancer. 
 
 
Cytoplasmic p53 and Its Transcription-Independent, Pro-apoptotic Function  
 
Early studies which employed temperature sensitive or DNA binding mutants of 
p53 suggested that it also functions in a transcription-independent manner to trigger 
apoptosis (Caelles et al., 1993; Haupt et al., 1995). This transcription-independent, pro-
apoptotic effect was later observed with wild type p53 in the absence of nuclei (Chipuk et 
al., 2003). Insights into the mechanism(s) responsible for this transcription-independent 
function came with observations that cytosolic p53 binds to anti-apoptotic BCL-2 family 
proteins and can also function as a direct activator of the pro-apoptotic BCL-2 effector 
proteins BAK and BAX to promote MOMP, cytochrome c release and apoptosis (Chipuk 
et al., 2005b; Chipuk et al., 2004; Chipuk et al., 2003; Leu et al., 2004; Mihara et al., 
2003). 
 
The p53 protein is constitutively expressed but rapidly degraded by an interaction 
with one or more of its transcriptional targets, such as the ubiquitin E3 ligase MDM2 
(Ashcroft et al., 2000). A variety of signals resulting from DNA damage, hypoxia, 
oncogene activation or other cellular stresses cause post-translational modification of 
p53, which disrupts its interaction with MDM2 and blocks p53 degradation (Kruse and 
Gu, 2009; Vogelstein et al., 2000). Upon stabilization, p53 accumulates in the nucleus 
and regulates gene expression, including transactivation of Puma. Concomitantly, p53 
accumulates in the cytosol where it is sequestered by anti-apoptotic BCL-2 proteins, 
especially BCL-xL (Chipuk et al., 2005b; Chipuk et al., 2004; Mihara et al., 2003).  Both 
PUMA protein and the PUMA BH3 domain peptide (PUMABH3) uniquely disrupt this 
interaction, releasing cytoplasmic p53 to activate MOMP and promote apoptosis (Chipuk 
et al., 2008; Chipuk and Green, 2005). 
 
 
Project Summary 
 
Apart from its nuclear role as a transcription factor, cytosolic p53 regulates 
apoptosis through interactions with the BCL-2 family of proteins. While lacking a classic 
BH3 domain, p53 none the less functions as a “direct activator” of apoptosis (Chipuk et 
al., 2004). By default, cytosolic p53 is sequestered in inactive complexes by BCL-xL. 
However, when expressed, PUMA binds BCL-xL and releases sequestered p53. Released 
p53, in turn, directly interacts with BAX triggering a cascade of events leading to 
permeabilization of the outer mitochondrial membrane, cytochrome c release, and, 
ultimately, apoptosis. Importantly, PUMA is the only de-repressor BH3-only protein that 
releases p53 from BCL-xL, unleashing p53’s full apoptotic potential.  
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The molecular mechanism by which PUMA disrupts the BCL-xL⋅p53 complex to 
promote MOMP and apoptosis remains unclear.  Previous structural studies revealed that 
the residues of p53 responsible for binding to BCL-xL do not occupy the canonical 
hydrophobic groove of BCL-xL akin to other pro-apoptotic BCL-2 proteins (e.g., BAK 
and BIM) (Petros et al., 2004a; Sot et al., 2007; Tomita et al., 2006), suggesting that 
PUMA does not simply compete with p53 for BCL-xL.  Therefore, we explored the 
BCL-xL⋅PUMA interaction at the structural, biochemical, and cellular levels to elucidate 
how PUMA influences the binding of p53, releasing it to induce MOMP and apoptosis. 
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CHAPTER 2.    REAGENTS AND EXPERIMENTAL PROCEDURES 
 
 
Reagents 
 
BH3 domain peptides: human BADBH3, BAKBH3, BAXBH3, BIDBH3, BIMBH3, 
HRKBH3, NoxaBH3, PUMABH3, and PUMABH3 W71A (>98% purity, Anaspec).  Fluorescein-
labeled PUMABH3 and alanine variants as well as the PUMA-BAD chimeric BH3 domain 
peptides (>98% purity, Hartwell Center for Bioinformatics and Biotechnology, St. Jude 
Children’s Research Hospital) were synthesized using standard Fmoc-based chemistry. 
Fluorescein- peptide labeling included an additional amino terminal fluorescein 
conjugation step. Baculoviral expressed p53 (p53Bac) was purchased from Protein One. 
BCL-2ΔC and C8-BID were purchased from R&D Systems. p53 immunopurified from 
MCF7 cells (p53UVIP) was made as described (Chipuk et al., 2004). Human full-length 
monomeric BAX was purified as described (Suzuki et al., 2000). pCMVneoBam-FLAG-
PUMA W71A, PUMA W71A in pET-30 (Novagen), BCL-xLΔC E7C, BCL-xLΔC 
H113A, BCL-xLΔC N175C, and BCL-xLΔC V135C,W181C (all in pET28a) were 
generated using the Stragene Quick Change Kit (Stratagene) with mutagenic 
oligonucleotides primers (Table A.1). All protein expression vector details are listed in 
Table A.2.  
 
 
Recombinant Proteins 
 
Recombinant human, full-length PUMA beta (hereafter referred to as PUMA) 
was expressed in E. coli strain BL21(DE3) (Novagen) using the pET-30a-vector. PUMA 
was expressed as a Histadine tag fusion by the addition of 1 mM IPTG. Cell pellets were 
resuspended in lysis buffer (50 mM Tris, pH 8.0, 500 mM NaCl, 5 mM imidazole, 5.0 
mM TCEP) plus EDTA-free protease inhibitor tablets (one tablet per 50 ml buffer) 
(Roche) and affinity purified with Ni-NTA Superflow resin (Qiagen). Fractions 
containing PUMA were pooled and further purified by reversed-phase high performance 
liquid chromatography (HPLC) using a semi-preparative C4 column (Vydac) and an 
acetonitrile linear gradient (Figure A.1). HPLC fraction two containing active PUMA 
was lyophilized and stored at -80 °C. Functional activity of recombinant PUMA protein 
was assessed by an in vitro cytochrome c release assay (Figure 2.1). The purity of the 
lyophilized protein was greater than 95% based on SDS-PAGE (Figure 2.2). 
 
Recombinant human PUMA W71A, PUMAN (PUMA residues 1-67) and PUMAC 
(PUMA residues 93-131) were expressed and purified to greater than 95% purity based 
on SDS-PAGE using the same procedures as described above for wild type PUMA beta 
(Figure 2.2). 
 
Recombinant human BCL-xLΔC (residues 1–209) was produced in E. coli strain 
BL21(DE3) using a pET-28 vector (Novagen). BCLxLΔC was expressed as a hexa 
histidine tagged fusion by the addition of 1 mM IPTG. Cells were resuspended in lysis 
buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5 mM imidazole) plus one EDTA-free   
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Figure 2.1 Recombinant PUMA and BCL-xL Proteins Are Active. 
Purified, murine liver mitochondria were treated with the indicated proteins before 
fractionation, SDS-PAGE, and western blot analysis for cytochrome c. C8-BID (caspase-
8-cleaved BID), BADBH3 (BAD BH3 domain peptide). 
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Figure 2.2 SDS-PAGE Analysis of the Indicated Recombinant Proteins. 
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Figure 2.2 (Continued).  
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protease inhibitor tablet per 50 ml of buffer (Roche) and affinity purified with Ni-NTA 
Superflow resin (Qiagen). The N-terminal hexa histidine tag was cleaved with thrombin 
protease (1 unit protease/mg protein) and the protein was diluted tenfold with anion 
exchange buffer (50 mM Tris, pH 8.0, 10 mM NaCl). The diluted sample was loaded 
onto a HiTrap Q HP column (GE Healthcare) and eluted with a linear gradient of 
increasing NaCl concentration. Fractions containing BCL-xLΔC were further purified by 
Superdex 200 gel filtration (Amersham) in 50 mM Tris pH 8.0 and 300mM NaCl, and the 
protein was concentrated using an Amicon Ultra filtration device (Millipore). 
Recombinant BCL-xLΔC was purified to greater than 95% purity based on SDS-PAGE 
(Figure 2.2). 
 
Human MCL-1ΔNΔC was produced in E. coli strain BL21(DE3) (Novagen) using 
the pET-151 vector and expressed as a hexa histidine tag fusion by the addition of 1 mM 
IPTG. Cell pellets were resuspended in lysis buffer (50 mM Tris, pH 8.0, 500 mM NaCl, 
5 mM imidazole, 5.0 mM TCEP) plus one EDTA-free protease inhibitor tablet per 50 ml 
of buffer (Roche) and affinity purified with Ni-NTA Superflow resin (Qiagen) followed 
by gel filtration on a Superdex 200 preparative gel filtration column (Amersham). 
Recombinant MCL-1ΔC was purified to greater than 95% purity based on SDS-PAGE 
(Figure 2.2). 
 
Human BFL-1ΔC was produced in E. coli strain BL21(DE3) (Novagen) using the 
pGEX-6P3 vector (GE Healthcare) and expressed as a glutathione S-transferase (GST) 
tag fusion by the addition of 0.2 mM IPTG and cultured at 18 ˚ C for 24 hr. Cell pellets 
were resuspended in lysis buffer (PBS) plus protease inhibitor mixture (Roche) and 
affinity purified with Glutathione Sepharose Fast Flow resin (GE Healthcare). The GST 
tag was cleaved by PreScission protease (GE Healthcare) and removed by a second GST 
affinity step. BFL-1ΔC was further purified by gel filtration on a Superdex 200 
preparative gel filtration column (Amersham). Recombinant BFL-1ΔC was purified to 
greater than 95% purity based on SDS-PAGE (Figure 2.2). 
 
BCL-xLΔLΔC, BCL-xLΔC E7C, BCL-xLΔC N175C, and BCL-xLΔC 
V135C,W181C were expressed and purified to greater than 95% purity based on SDS-
PAGE (Figure 2.2) using the same methods described above for BCL-xLΔC. 
 
 
Calorimetric Studies 
 
Most ITC experiments were done using a VP-ITC (Microcal) calorimeter. 
Titrations consisted of a preliminary 2 μl injection of 100 μM PUMA or various BH3 
domain peptides, followed by several injections of 6 μl of either PUMA or BH3 domain 
peptide into a solution of 10 μM BCL-xLΔC monomer, BCL-xLΔC apo-dimer, MCL-
1ΔC, or BFL-1ΔC. Experiments were conducted at 25 °C in 20 mM Tris, pH 7.4, 100 
mM NaCl and 1 mM TCEP. The time interval between injections was 300 sec. The 
instrument was regularly calibrated using water into water titratrions. Thermodynamic 
parameters were obtained using Origin software (OriginLab) using routines provided by 
the manufacturer. Heats of reaction were corrected for the effect of dilution by injection 
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of protein or peptide titrant from the syringe into ITC buffer alone followed by 
subsequent subtraction of these heats from the original experiment.  
 
ITC experiments for BCL-xLΔC and p53Bac were done using an ITC-200 
(Microcal) calorimeter. Titrations consisted of a preliminary 0.5 μl injection of BCL-
xLΔC or BCL-xLΔC apo-dimer, followed by several injections of 2 μl of either BCL-
xLΔC or BCL-xLΔC apo-dimer into a solution of p53Bac. Experiments were conducted at 
15 °C in 20 mM Tris, pH 7.5, 50 mM NaCl and 1 mM TCEP. The time interval between 
injections was 180 sec. Despite extensive, simultaneous dialysis of all proteins against 
ITC buffer to remove the glycerol from p53Bac (provided in 20% glycerol by the 
manufacturer), a buffer mismatch remained between the final protein samples. A control 
experiment was performed in which BCL-xLΔC was titrated into ITC buffer to measure 
the heat of dilution and obtain a control isotherm. A point-by-point subtraction of the 
control isotherm from the experimental binding isotherm was performed to obtain final 
isotherms representative of heat changes produced by BCL-xLΔC or BCL-xLΔC apo-
dimer binding to p53Bac, which was fit using Origin 7.0 software (OriginLab). 
 
 
Circular Dichroism Spectropolarimetry 
 
CD data were collected on an Aviv 62A DS spectropolarimeter. Far-UV CD 
wavelength scans (260–195 nm) were performed with 5 μM PUMA protein or 50 μM 
PUMABH3 in 20 mM potassium phosphate pH 7.0 using the following standard 
measurement parameters: wavelength, 195-260 nm; step resolution, 0.5 nm; speed, 20 
nm/min; accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length, 0.1 cm. 
Temperature was maintained at 25 °C with a Peltier thermoelectric device. Molar 
ellipticity was calculated using the following equation: 
 
                                                      [Θ] = [(100)(Θobs)]/[(c)(l)]  (Eq. 2.1) 
 
where [Θ] is molar ellipticity, Θobs is observed ellipticity, c is molar concentration, and l 
is the cuvette pathlength in meters.  
 
NMR Spectroscopy 
 
 15N-labeled BCL-xLΔLΔC and 15N-labeled PUMA for NMR studies were 
expressed using a MOPS-based minimal media containing 15N-NH4Cl (Lacy et al., 2004) 
and purified using the procedures described above for the respective unlabled proteins. 
15N-labeled BCL-xLΔC proteins were prepared at 0.3 mM in 20 mM sodium phosphate 
pH 7.0, 3 mM DTT, and 0.5 mM EDTA. 15N-labeled PUMA was prepared at 0.3 mM in 
20 mM deuterated Tris (Cambridge), pH 7.1, 150 mM NaCl, and 5 mM deuterated DTT 
(Cambridge). Data were acquired on Bruker 600 MHz and 800 MHz spectrometers 
equipped with cryogenically-cooled, triple-resonance single-axis gradient probes. One 
dimensional (1D) spectra were acquired at 30 ˚ C using the zgesgp pulse sequence 
provided by Bruker (Hwang, 1995). Two dimensional (2D) 1H-15N HSQC or TROSY 
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spectra were acquired at 25 or 30 ˚ C using the hsqcetf3gpsi and trosyf3gpphsi19 Bruker 
pulse sequences, respectively (Schleucher et al., 1994; Zhu et al., 1999). Spectra were 
processed using NMRPipe (Delaglio et al., 1995) and analyzed using TopSpin (provided 
by Bruker) and CARA  software. 
 
 
Analytical Ultracentrifugation 
 
Dr. Amanda Nourse at the St. Jude Hartwell Center performed analytical 
ultracentrifugation (AUC) using the indicated purified proteins and BH3 domain 
peptides.  
 
For sedimentation velocity experiments, BCL-xLΔLΔC, BCL xLΔLΔC·BIMBH3 
and BCL-xLΔLΔC·PUMABH3 complex, all at approximately 1.1 mg/ml in 20 mM Tris 
pH 7.5, 100 mM NaCl were subjected to sedimentation velocity ultracentrifugation in a 
ProteomeLab XL-I analytical ultracentrifuge with a Beckman An-60 Ti rotor and cells 
containing sapphire windows and charcoal-filled Epon double-sector centerpieces 
(Beckman Coulter, Fullerton, CA). The density and viscosity of the buffer were 
calculated from their composition, and the partial specific volume and molecular weights 
of the protein and complexes were calculated based on their amino acid composition 
using the software SEDNTERP (Laue et al., 1992). All samples were dialysed against the 
ultracentrifugation buffer, and the dialysate was used as an optical reference. 
Temperature equilibrium at 20 °C was established in the instrument prior to the run over 
a period of at least 3 hr. Ultracentrifugation was performed at 60,000 rpm for 12 hr.  
Fringe displacement data at time intervals of 1.0 min were collected with the Rayleigh 
interference system and analysed with SEDFIT software using the model for continuous 
sedimentation coefficient distribution c(s) with deconvolution of diffusional effects 
(Schuck, 2000; Schuck et al., 2002). The sedimentation coefficient distribution c(s) was 
calculated with maximum entropy regularization at a confidence level of p = 0.7 and at a 
resolution of sedimentation coefficients of n = 120. The positions of the meniscus and 
bottom, as well as time-invariant and radial noises, were fitted.  
 
Sedimentation equilibrium experiments were performed on BCL-xLΔLΔC, BCL-
xLΔLΔC·BIMBH3, BCL-xLΔLΔC·PUMABH3 complexes (sample concentrations of 1.0-16 
μM), and BCL-xLΔC·PUMABH3 (sample concentrations of 0.19, 0.42, and 1.14 μM) in 
20 mM sodium phosphate pH 7.0, 100 mM NaCl buffer with a Beckman An-50 Ti rotor 
and cells containing quartz windows and charcoal-filled Epon double-sector center pieces 
(Beckman Coulter, Fullerton, CA). The density and viscosity of the buffer were 
calculated as described above. The buffer eluent of the size-exclusion column was used 
as an optical reference. Equilibrium was attained at 24 hr at a rotor temperature of 4 °C at 
increasing speeds of 15, 22 and 28 thousand rpm.  120 µL of each sample was loaded into 
double-sector centrepieces and absorbance distributions recorded at 230 and 280 nm in 
0.001 cm radial intervals with 20 replicates for each point.  Global least squares 
modelling of all datasets (all concentrations, rotor speeds and wavelengths) were 
performed with the software SEDPHAT using a single species model as well as a 
reversible monomer-dimer self-association model (Balbo et al., 2007). 
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Crystallization, Data Collection, and Refinement 
 
Crystals of BCL-xLΔC were grown at 18 °C by hanging-drop vapor diffusion 
using equal volumes of 1.5 mM protein and precipitant (1.5 M lithium sulfate, 0.1 M tri-
sodium citrate pH 5.6, and 2.0 M ammonium sulfate) (Figure 2.3). Crystals were 
cryoprotected in mother liquor supplemented with 30% glycerol and flash-frozen in 
liquid nitrogen. Diffraction data (Figure 2.3) were collected at 100 K at the Southeast 
Regional Collaborative Access Team (SER-CAT) 22-ID synchrotron beamline using a 
CCD detector and a beam wavelength of 1.0 Å. Data were indexed and scaled using 
HKL2000 (Otwinowski and Minor, 1997). The structure was calculated to 2.1 Ǻ 
resolution by direct refinement using CNS (Brunger et al., 1998) and Xtalview (McRee 
and Israel, 2008). Data processing parameters are summarized in Table 2.1.  
 
The BCL-xLΔC⋅PUMABH3 complex was prepared by adding PUMABH3 in a 1:1.2 
molar ratio to 1.5 mM BCL-xLΔC in 50 mM Tris, 100 mM NaCl pH 7.5.  Crystals were 
grown at 18 °C by hanging-drop vapor diffusion mixing equal volumes of protein 
solution and precipitant (0.2 M calcium chloride, 0.1 M sodium acetate pH 4.6 and 20% 
isopropanol) (Figure 2.3). The final pH of the drop was approximately 7.2. Crystals were 
cryoprotected in mother liquor supplemented with 30% glycerol and flash-frozen in 
liquid nitrogen. Diffraction data (Figure 2.3) were collected at 100 K at the Southeast 
Regional Collaborative Access Team (SER-CAT) 22-ID synchrotron beamline using a 
CCD detector and a beam wavelength of 1.0 Å. Data were indexed and scaled using 
HKL2000 (Otwinowski and Minor, 1997). The structure of the BCL-xL∆C·PUMABH3 
complex was determined by molecular replacement using PHASER (Zwart et al., 2008). 
Model building was performed using COOT (Emsley and Cowtan, 2004), and iterative 
rounds of refinement were performed using CNS (Brunger et al., 1998) and Refmac using 
TLS refinement (Murshudov et al., 1997). Data processing parameters are summarized in 
Table 2.2. All structural figures were generated with PyMOL (www.pymol.org). 
 
 
Fluorescence Spectroscopy 
 
The affinity of fluorescein-labeled PUMABH3 for BCL-xLΔC was determined by 
fluorescence anisotropy using a Fluorolog-3 spectrofluorometer (Jobin Yvon Inc). All 
experiments were performed at 30 °C with continuous stirring. Dilution buffer for all 
protein and peptide stocks was 120 mM sodium phosphate pH 7.5. The concentrations of 
the DMSO peptide stock solutions were 0.5-1.5 mM, as determined by tryptophan 
absorbance at 280 nm or amino acid analysis. The final DMSO concentration for all 
samples was less than 1%. The binding affinities of peptides to BCL-xLΔC were 
measured from the anisotropy of fluorescein fluorescence emission as a function of 
increasing BCL-xLΔC concentration (Table A.3). A five min time interval was used to 
allow every addition of BCLΔC to reach equilibrium. The excitation and emission 
wavelengths were 494 and 525 nm, respectively. The grating factor was set to 0.5 mm to 
reduce noise. All data points represent the mean of at least two independent experiments. 
Fluorescence anisotropies were converted to fraction of ligand bound (Lakowicz, 1983) 
using the following equation:  
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Figure 2.3 Protein Crystals and Respective Diffraction Data Images. 
(A) Crystals of BCL-xLΔC prior to harvesting and x-ray diffraction. (B) Representative 
BCL-xLΔC crystal x-ray diffraction image taken at Ф = 90°. (C) Crystals of the BCL-
xLΔC·PUMABH3 complex prior to harvesting and x-ray diffraction. (D) Representative 
BCL-xLΔC crystal x-ray diffraction image taken at Ф = 90°.  
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Table 2.1 BCL-xLΔC Structure Data and Refinement Statistics. 
 
aNumbers in parentheses refer to the highest resolution shell. 
b Rwork  = S llFobsl – lFcalcll / S lFobsl where Fobs and Fcalc are observed and model structure 
factors, respectively.  
Rfree was calculated using a randomly selected set (5 %) of reflections.  
Data  BCL-xLΔC 
Data Collection  Values 
Wavelength (Å)  1.0 
Space Group  P41212 
Cell Dimension   
a, b, c (Å)  63.1, 63.1, 111.0 
α, β, γ (°)  90.0, 90.0, 90.0 
Resolution (Å)  50.0-2.1  
Rsyma (%)  8.5 (43.7) 
 
I/σI  49.8 (4.0)a 
Completeness  98.9 (96.8) 
Redundancy  16.0 (10.9) 
Data Refinement   
Resolution (Å)  50.0-2.1 
No. Reflection  13194 
Rwork/Rfreeb  .225/.248 
No. Atoms   
Protein  1153 
Water  48 
Average B-factors (Å2)  38 
R.M.S. Deviations  38 
Bond Lengths  0.006 
Bond Angles  1.1 
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Table 2.2 BCL-xLΔC·PUMABH3 Structure Data and Refinement Statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Numbers in parentheses refer to the highest resolution shell. 
b Rwork  = S llFobsl – lFcalcll / S lFobsl where Fobs and Fcalc are observed and model structure 
factors, respectively.  
Rfree was calculated using a randomly selected set (5 %) of reflections.  
Data  BCL-xLΔC·PUMABH3 
Data Collection   
Wavelength (Å)  1.0 
Space group  P4222 
Cell Dimension   
a, b, c (Å)  94.8, 94.8, 111.5 
α, β, γ (°)  90.0, 90.0, 90.0 
Resolution (Å)  50.0-2.9  
Rsyma (%)  9.4 (38) 
I/σI  38.4 (3.28) 
Completeness  95.6 (65.5) 
Redundancy  21.7 (8.8) 
Refinement   
Resolution (Å)  43.6-2.9 
No. Reflection  10731 
Rwork/Rfreeb  .231/.281 
No. Atoms   
Protein  349 
Water  6 
Average B-factor (Å2)  73 
R.M.S. Deviations   
Bond Lengths  0.011 
Bond Angles  1.2 
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                                             Fb = (r - rfree)/[(rbound – r)(q) + r-rfree]  (Eq. 2.2) 
 
where Fb is the molar fraction of bound ligand, r is the anisotropy value at a given 
titration point, rfree is the anisotropy value of free ligand at a given titration point, rbound is 
the anisotropy value of bound ligand at a given titration point, and q is the ratio of 
fluorescence intensities of the bound and free ligand. Binding affinities were calculated 
by non-linear curve fitting (Prism, Graphpad) (Table A.2) using the following equation: 
 
                                                   Y = [(Bmax)(X)]/[X + Kd]  (Eq. 2.3) 
 
where Y is the fraction of total bound ligand, Bmax is the maximum concentration of 
ligand binding sites, X is the concentration of labeled ligand, and Kd is the equilibrium 
dissociation constant of the labeled ligand. 
 
 
BCL-xL Crosslinking 
 
Structure-based crosslinking of BCL-xLΔC E7C and BCL-xLΔC N175C cysteine 
mutants was performed based on the previously described experiment (O'Neill et al., 
2006) with minor modifications. Briefly, the indicated concentrations of the BCL-xLΔC 
E7C and BCL-xLΔC N175C were mixed at equimolar concentrations and incubated with 
or without a 5-fold molar excess of the irreversible, sulfhydryl crosslinking agent 
bismaleimidohexane (BMH) (Thermo Scientific) in the presence or absence of the 
indicated concentration of PUMABH3. SDS-PAGE followed by western blot analysis for 
BCL-xL was used to determine the oligomeric status of BCL-xL for each treatment. 
Treatment of BCL-xLΔC or the two BCL-xLΔC cysteine mutants individually or mixed 
as described above with buffer alone served as negative controls. 
 
 
Disulfide Bond Introduction 
 
Creation of a BCL-xLΔC double cysteine mutant construct that would form a 
disulfide bond and “trap” the protein in its monomeric form without disrupting the BH3 
domain binding groove was guided using the software Disulfide By Design 
(Dombkowski, 2003). A BCL-xLΔC double cysteine mutant was generated and screened 
for successful disulfide bond formation using a free thiol assay as described (Pham et al., 
2007). 
 
 
Electrophoresis, Immunoblotting, and Co-immunoprecipitation 
 
SDS-PAGE was conducted using the Criterion XT 4-12% gel system (BioRad) 
with 1X MOPS buffer at 150 V. Native PAGE was performed on 18%  
Tris-HCl polyacrylamide gels (BioRad) in native running buffer (25 mM Tris pH 8.3, 
192 mM glycine), and samples were prepared using the Native PAGE Sample Loading 
Kit (Invitrogen). For western blot analysis, proteins were transferred to nitrocellulose by 
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standard conditions, blocked in 5% milk/Tris Buffered Saline Tween-20 (TBST) and 
primary antibodies (in blocking buffer: BCL-xL (SantaCruz Biotechnology, clone S-18) 
1:1,000; cytochrome c (Pharmingen, clone 7H8.2C12) 1:1,000; p53 (SantaCruz 
Biotechnology, clone D07) 1:1,000; PUMA (Cell Signaling or Sigma) 1:1,000 and FLAG 
(SantaCruz Biotechnology, clone M2) 1:1,000 were incubated overnight at 4 °C. The 
secondary antibody (1:5,000 in blocking buffer) was incubated at 25 °C for 1 hr before 
standard enhanced chemiluminescence detection. Blocking buffer consisted of 5.0 % 
lowfat milk in TBST. 
 
BCL-xL∆C⋅p53 complexes were produced for co-immunoprecipitation by 
combining 10 nM recombinant BCL-xLΔC with purified baculovirus-expressed p53 
(ProteinOne) or p53UVIP in HE buffer (10 mM HEPES, pH 7.4, 1 mM EDTA) overnight 
at 4 °C (Chipuk et al., 2005b; Chipuk et al., 2004). Anti-BCL-xL (clone H-5) or anti-p53 
(clone DO7) antibodies and protein A/G-agarose beads (Thermo Scientific) were added, 
incubated overnight at 4 °C, and washed 3 times to remove any unbound material. 
Protein A/G-agarose beads were boiled in 1X SDS-PAGE loading dye, and precipitated 
proteins were visualized by standard SDS-PAGE and western blot techniques. 
 
FLAG-PUMA co-immunoprecipitation experiments were performed by Dr. Jerry 
Chipuk in the laboratory of Dr. Douglas Green (Department of Immunology, St. Jude). 
For FLAG-PUMA co-immunoprecipitations, cells were lysed in 1% CHAPS, 150 mM 
NaCl, 5 mM MgCl2, 1 mM EDTA and 10% glycerol.  Lysates (100 μg) were combined 
with 1 μg FLAG M2 antibody, 25 μl 50% slurry of Protein A/G Plus Agarose (Santa 
Cruz Biotechnology) and incubated end over end for 2 hours at 4°C.  Agarose beads were 
washed 3 times in lysis buffer, eluted with 100 µg/ml FLAG peptide, and precipitated 
proteins were visualized by standard SDS-PAGE and western blot techniques. 
 
 
Heavy Membrane Preparation and Cytochrome c Release 
 
Heavy membrane preparation and cytochrome c release assays were performed by 
Dr. Jerry Chipuk in the laboratory of Dr. Douglas Green (Department of Immunology, St. 
Jude). Heavy membrane fractions (referred to as mitochondria) were purified from 
murine liver, usually female, under 3 months, using dounce homogenization and 
differential centrifugation in mitochondrial isolation buffer (MIB: 200 mM mannitol, 68 
mM sucrose, 10 mM HEPES-KOH pH 7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.1 
% BSA). 
 
For MOMP assays, mitochondria were incubated in MIB supplemented to 110 
mM KCl (mitochondrial assay buffer, MAB), plus or minus proteins and peptides (final 
concentrations and order of addition are indicated in the text and figure legends below) 
for 60 minutes at 37 °C. Reactions were then fractionated into supernatant and pellet by 
centrifugation at 5,500 x g for 5 min, and analyzed by SDS-PAGE and western blot with 
an anti-cytochrome c antibody.   
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For MOMP reconstitution studies wherein bak-/-bax-/-mitochondria were used, 
heavy membrane fractions were isolated from the livers of poly(deoxyinosinic-
deoxycytidylic) acid sodium salt (poly-dIdC) treated MxCre bak-/-baxf/- mice. Three 
separate injections (each separated by one day) of poly-dIdC allowed interferon 
stimulation, especially in the liver. Induced interferon promoted activation of the Mx 
promoter, driving expression of Cre recombinase and subsequent removal of the 
remaining MxCre floxed bax allele. 
 
For concurrent binding and MOMP assays, 10 nM BCL-xL∆C⋅p53UVIP complexes 
were produced and captured by combining recombinant BCL-xL∆C, p53UVIP and Ni+2-
NTA agarose in PBS at 25 ºC for 2 hrs before pelleting (1,000 x g, 5 minutes at 25 ºC) 
and washing the complex three times with PBS.  The final pellet was resuspended in 
MAB (without EDTA or EGTA), indicated peptides were added along with BAX and 
mitochondria, and incubated for 1 hr at 37 ºC before fractionation and western blot 
analysis for cytochrome c, BCL-xL∆C and p53UVIP. 
 
 
Cell Culture, Transfection, and Survival Assays 
 
Cell culture, transfection, and survival assays were performed by Dr. Jerry Chipuk 
in the laboratory of Dr. Douglas Green (Department of Immunology, St. Jude). Mouse 
embryonic fibroblasts (MEFs; SV40 immortalized wild type, p53-/- and puma-/-) were 
cultured in DMEM containing 10% FBS, 100 mM 2-mercaptoethanol, 2 mM L-
glutamine and antibiotics. The MEF panel was routinely replaced to minimize culture-
induced accumulation of direct activator proteins. Cells were transfected using 
Lipofectamine 2000 according to the manufacturer’s instructions for 6 hours under 
serum-free conditions (pCMV5 and pCMVneoBam-FLAG-PUMA wild type or W71A). 
Green fluorescent protein (pUS9-GFP) was co-transfected as an efficiency marker (30-
50% of cells were usually transfected). The next day, cells were treated with indicated 
doses of TNF/CHX or UV for 6 h and 24 h, respectively; before trypsinization, RIPA 
lysis, immunoprecipitation and/or AnnexinV-PE labeling and analysis by flow cytometry. 
 
 
Microinjection and Confocal Microscopy 
 
Microinjection and confocal microscopy experiments were performed by Dr. 
Jerry Chipuk in the laboratory of Dr. Douglas Green (Department of Immunology, St. 
Jude). MCF-7 SMAC-GFP cells (Munoz-Pinedo et al., 2006) were plated on glass bottom 
dishes (MatTek) the day before injection in DMEM (containing: 200 mM L-glutamine, 
10% heat inactivated FBS and antibiotics) and incubated at 37 °C with 5% CO2.  At the 
time of injection, cells were approximately 90% confluent and treated with 20 µM Q-
VD-OPh (R&D Systems) (except for TNF/CHX treated cells). Cells were co-injected 
with Texas Red dextran (0.2 µg/µl, 10 kDa, Invitrogen, Molecular Probes) in HE buffer 
(10 mM HEPES pH 7.4, 1 mM EDTA); the needle concentrations were: 5.5 µM C8-BID, 
BCL-xL∆C monomer (50 µM), and BCL-xL∆C apo-dimer (25 µM). Approximately 10-
50 femtoliters were injected per cell; the uncertainty in injection volume was due to the 
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back pressure within the cell, which was dictated by where in the cytoplasm the needle 
entered. Cells were injected using an Eppendorf InjectMan NI2/FemtoJet microinjection 
system (Brinkmann Instruments), mounted on a Nikon TE2000-U inverted microscope 
(Nikon USA), with an ELDW 40X Plan Fluor phase-contrast objective (NA 0.6). Cells 
were kept in the stage for less than 20 min at a time. Injection parameters: Pi: 30-120 
hPa, Ti: 0.5 s, Pc: 20 hPa. Immediately after injection cells were allowed to recover at 37 
°C, 5% CO2. Confocal microscopy of live cells was performed with a Marianas spinning 
disk confocal imaging system (Intelligent Imaging Innovations/3i) consisting of a CSU22 
confocal head (Yokogowa Electric Corporation), DPSS lasers (CrystaLaser) with 
wavelengths of 445 nm, 473 nm, 523 nm, 561 nm, and 658 nm, and a Carl Zeiss 200M 
motorized inverted microscope (Carl Zeiss MicroImaging), equipped with spherical 
aberration correction optics (3i). Temperature was maintained at 37 °C and 5% CO2 using 
an environmental control chamber (Solent Scientific).  Images were acquired with a Zeiss 
Plan-Neofluar 40x 1.3 NA DIC objective on a CascadeII 512 EMCCD (Photometrics), 
using SlideBook 4.2 software (3i) after indicated treatments. Greater than 200 injected 
cells were analyzed for each condition. 
 
 
Protein Concentration Determination 
 
The concentrations of all prepared recombinant proteins were determined by UV 
absorbance at 280 nm in a denaturing buffer containing 20 mM phosphate, pH 6.5, 6.0 M 
guanidine hydrochloride (Bairoch et al., 2005; Gill and von Hippel, 1989). The molar 
extinction coefficients were determined using the ProteinParameters tool (ExPASy 
server; https://us.expasy.org/tools/protparam.html). 
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CHAPTER 3.    RESULTS 
 
 
PUMA Is an Intrinsically Disordered Protein that Induces BCL-xL Dimerization 
 
We generated purified recombinant, full-length human PUMA beta (hereafter 
referred to as PUMA) and examined its structural features.  From CD and NMR 
spectroscopy analyses (Figure 3.1), we determined that full-length PUMA protein is an 
intrinsically disordered protein (IDP), which is similar to other BH3-only proteins (Hinds 
et al., 2006). The CD spectrum of PUMA exhibited the features of an extensively 
disordered protein, with a minimum value of molar ellipticity at 200 nm and no features 
indicative of highly populated secondary structure (Figure 3.1A). A weak feature at 222 
nm is indicative of α-helical secondary structure and is accounted for by the nascent 
helical structure within the BH3 domain by comparison of CD spectra from PUMA and 
the PUMABH3 as well as amino and carboxyl terminal fragments of PUMA lacking the 
BH3 domain [PUMAN and PUMAC (residues 1-67 and 93-131, respectively); Figure 
3.1A]. Further, the 2D 1H-15N heteronuclear single-quantum coherence (HSQC) NMR 
spectrum of 15N-labeled PUMA exhibited limited 1H chemical shift dispersion (≤ 1 ppm) 
(Figure 3.1B), which is characteristic of IDPs (Kriwacki et al., 1996). The protein 
exhibited the appropriate number of peaks (~15 Gly residues), indicating it was 
predominantly a single, homogenous species. 
  
Previous biochemical studies suggested that the PUMA BH3 domain is the 
principal site of interaction with BCL-xL (Chen et al., 2005; Chipuk et al., 2005b; Chipuk 
et al., 2008; Kuwana et al., 2005). We confirmed this by comparing the affinities of a 
PUMA BH3 domain peptide (PUMABH3) and PUMA protein for binding BCL-xLΔC 
using isothermal titration calorimetry (ITC) (Figure 3.2). These results showed that both 
full-length PUMA and PUMABH3 bound BCL-xL equivalently. 
 
To further analyze binding of PUMABH3 to BCL-xLΔC, sedimentation velocity 
analytical ultracentrifugation (AUC) experiments were performed. A functional BCL-xL 
protein lacking the unstructured loop as well as the C-terminal 22 residues, hereafter 
referred to as BCL-xLΔLΔC (Muchmore et al., 1996b), was used for AUC experiments. 
While monomeric BCL-xLΔLΔC and the BCL-xLΔLΔC⋅BIMBH3 complex (which 
exhibits 1:1 stoichiometry) (Liu et al., 2003), sedimented with s values corresponding to 
the expected masses (monomeric BCL-xLΔLΔC: theoretical mass = 20.8 kDa, observed 
mass = 20.4 kDa; BCL-xLΔLΔC⋅BIMBH3: theoretical mass = 23.9 kDa, observed mass = 
23.9 kDa), the BCL-xLΔLΔC⋅PUMABH3 complex sedimented with an s value consistent 
with a 2:2 heterodimeric species (2:2 BCL-xLΔLΔC⋅PUMABH3: theoretical mass = 47.6 
kDa, observed mass = 46.7 kDa) (Figure 3.3). Sedimentation equilibrium AUC 
experiments yielded molecular weight values for BCL-xLΔLΔC, the BCL-
xLΔLΔC⋅BIMBH3 complex, and the BCL-xLΔLΔC⋅PUMABH3 complex that were in 
agreement with the sedimentation velocity AUC data.  Collectively, these AUC data 
strongly suggested that addition of PUMABH3-induced BCL-xLΔLΔC dimerization. BCL-
xL has previously been shown to dimerize via swapping of the protein’s C- terminal 22 
residues (Jeong et al., 2004), and a crystal structure of a domain-swapped BCL-xLΔC 
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Figure 3.1 PUMA Is an Intrinsically Disordered Protein. 
(A) The circular dichroism (CD) spectrum of PUMA exhibited a minimum value of 
molar ellipticity at 200 nm, consistent with a lack of highly populated secondary 
structure. A weak feature at 222 nm indicated alpha-helical secondary structure that can 
be attributed to nascent helical structure within the PUMA BH3 domain by comparison 
of CD spectra for PUMA with spectra for peptides corresponding to the PUMA BH3 
domain and the amino and carboxyl terminal fragments of PUMA lacking the BH3 
domain (PUMABH3, PUMAN, and PUMAC, respectively). (B) The 2D 1H-15N HSQC 
spectrum of PUMA exhibited the appropriate number of resonances. PUMA resonances 
were dispersed over a narrow 1H chemical shift range (≤ 1 ppm) indicating that PUMA is 
intrinsically disordered. 
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Figure 3.2 The BH3 Domain of PUMA Is Sufficient for Binding BCL-xL. 
ITC binding isotherms recorded for BCL-xLΔC titrated into a solution of PUMABH3 (A) 
or PUMA (B). Errors represent the standard deviation calculated from at least two 
independent experiments. 
  
41 
 
 
 
 
Figure 3.3 Analytical Ultracentrifugation of Indicated BCL-xLΔC Species. 
(A) The sedimentation velocity profiles, s values, and experimental molecular masses for 
BCL-xLΔLΔC (black), BCL-xLΔLΔC·BIM BH3 (red), and BCL-xLΔLΔC·PUMABH3 
(blue). Sedimentation equilibrium AUC analysis of monomeric BCL-xLΔLΔC, BCL-
xLΔLΔC·BIMBH3 domain peptide and BCL-xLΔLΔC·PUMABH3 domain peptide.  (B-D) 
Solid lines represent the global nonlinear least squares best-fit to a single species model 
with a molar mass of 22.9 kDa for BCL-xLΔLΔC (black), 24.9 kDa for BCL-
xLΔLΔC·BIMBH3 (1:1) (red) and 44.7 kDa for BCL-xLΔLΔC·PUMABH3 (2:2) (blue). The 
RMSD for the respective fits were between 0.0023 and 0.0030 absorbance units. For 
clarity only the samples with respective loading protein concentrations of 4.6, 5.6 and 2.6 
µM and centrifuged at the rotor speed 28,000 rpm are shown. 
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apo-dimer (induced via purification of the protein under extreme alkaline conditions) was 
previously reported (O'Neill et al., 2006). 
 
To investigate the phenomenon of PUMABH3-induced BCL-xL dimerization, we 
established a native polyacrylamide gel electrophoresis (PAGE) gel system to resolve apo 
(i.e., ligand-free) monomeric BCL-xLΔC and the BCL-xLΔC⋅PUMABH3 dimer.  A stable, 
unbound, “BCL-xLΔC apo-dimer” was prepared by heat treatment, as described 
(Denisov et al., 2007b); BCL-xLΔC monomer and BCL-xLΔC apo-dimer were used as 
standards in our native PAGE assays.  
 
 Consistent with the AUC results described above, the addition of PUMABH3 to 
BCL-xLΔC monomer resulted in dose-dependent, stoichiometric formation of the 
dimeric BCL-xL∆C⋅PUMABH3 complex (Figure 3.4A). BCL-xL∆C G138A, a mutant 
form of BCL-xL that does not bind to pro-apoptotic effector BCL-2 proteins (i.e., BAK or 
BAX) or BH3-only proteins (Yang et al., 1995), was used as a negative control in the 
native PAGE assay. As expected, the addition of PUMABH3 to BCL-xL∆C G138A did 
not cause dimerization, whereas dimerization was observed with wild type BCL-xLΔC 
(Figure 3.4B).  
 
To determine if BCL-xL∆C dimerization was specific to the PUMA BH3 domain, 
seven additional BH3 domain peptides (Table 3.1) were evaluated for inducing BCL-
xL∆C dimerization using the native PAGE assay. As expected, the addition of a two-fold 
molar excess of PUMABH3 to BCL-xLΔC monomer resulted in complete BCL-xL∆C 
dimerization, whereas the same concentration of BH3 domain peptides from BAD, BAK, 
BAX, BID, BIM, HRK and Noxa failed to induce BCL-xL∆C dimerization (Figure 
3.4C). ITC analyses confirmed that all but one of the BH3 domain peptides used in this 
assay were capable of binding to BCL-xLΔC (Figure 3.5). As a negative control, the 
NoxaBH3 did not bind to BCL-xL∆C due to a restricted binding pattern for anti-apoptotic 
proteins (NoxaBH3 only binds BFL-1 and MCL-1 (Chen et al., 2005)). All thermodynamic 
parameters were calculated (Table A.4)  
 
The ability of the PUMABH3 to induce dimerization of other anti-apoptotic BCL-2 
proteins (e.g., BCL-2, BFL-1 and MCL-1) was also evaluated. The addition of a two-fold 
molar excess of PUMABH3 to BCL-2ΔC, BFL-1ΔC or MCL-1ΔC did not result in the 
formation of higher-order, peptide-bound species (Figure 3.4D), which is consistent with 
recently reported structures of the BFL-1ΔC·PUMABH3 (Smits et al., 2008) and MCL-
1ΔC·PUMABH3 (Day et al., 2008) complexes. These results suggested that PUMABH3-
induced dimerization of the anti-apoptotic BCL-2 family member BCL-xL was unique to 
the BCL-xL·PUMA interaction.  
 
 
PUMA-induced BCL-xL Dimer Is Not in Dynamic Equilibrium 
 
We then examined the stability of the PUMA-induced BCL-xL dimer by several  
approaches. PUMABH3 plus BCL-xLΔC was resolved by analytical size exclusion 
chromatography, collected, and the diluted material was subsequently rerun. In both cases   
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Figure 3.4 Native PAGE Analysis of PUMA·Anti-apoptotic BCL-2 Family 
Protein Complexes. 
(A)The addition of PUMABH3 to BCL-xLΔC monomer caused the stoichiometric 
conversion of BCL-xL∆C to a dimeric species. BCL-xLΔC (50 µM) was treated with 
PUMABH3 (0, 0.25, 0.5, 0.75 and 1.0 molar equivalents) for one hour at 37 °C and 
subjected to native PAGE followed by Coomassie staining.  BCL-xLΔC monomer and 
BCL-xLΔC apo-dimer were used as native PAGE controls.  (B) PUMABH3-induced 
dimerization of BCL-xLΔC required G138 within the BCL-xL∆C canonical BH3 
domain-binding groove. The BCL-xLΔC G138A mutant (50 μM) was treated with 
PUMABH3 (100 μM) for one hour at 37 °C and subjected to native PAGE followed by 
Coomassie staining. (C) BCL-xLΔC (50 μM) was treated with the indicated BH3 domain 
peptides (100 μM) for one hour at 37 °C and subjected to native PAGE followed by 
Coomassie staining. NoxaBH3 was used as a negative control. (D) PUMABH3 did not 
induce the dimerization of other anti-apoptotic BCL-2 proteins. BCL-2ΔC, BFL-1ΔC or 
MCL-1ΔC (50 µM) was treated with PUMABH3 (100 µM) for one hr at 37 °C and 
subjected to native PAGE followed by Coomassie staining. 
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Table 3.1 BH3 Domain Peptide Sequences. 
 
BH3 Domain Peptide Peptide Sequence (N- to C-terminal) 
BAD NLWAAQRYGRELRRMSDEFVDSFKK 
BAK PSSTMGQVGRQLAIIGDDINR 
BAX PQDASTKKSECLKRIGDELDSNMEL 
BID QEDIIRNIARHLAQVGDSMDRSIPP 
BIM DMRPEIWIAQELRRIGDEFNAYYAR 
HRK RSSAAQLTAARLKALGDELHQRTMW 
Noxa PAELEVECATQLRRFGDKLNFRQKL 
PUMA EEQWAREIGAQLRRMADDLNAQYER 
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Figure 3.5 ITC Analysis of BH3 Domain Peptides Binding BCL-xLΔC. 
(A) A 100 μM solution of the indicated BH3 domain peptides was titrated from the ITC 
syringe into the ITC cell containing 10 μM BCL-xLΔC. Data were fit using a 1:1 binding 
model. Errors represent the standard deviation calculated from at least two independent 
experiments. 
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BCL-xLΔC resolved as a single peak with a molecular weight consistent with a 2:2 
heterodimeric BCL-xLΔC·PUMABH3 complex (Figure 3.6A). Similarly, sedimentation 
equilibrium AUC was again performed at different concentrations of BCL-xL∆C 
·PUMABH3, and in agreement with the previously obtained data from Figure 3.3D, results 
indicated formation of a stable dimer (Figure 3.6B). Finally, full-length PUMA and 
BCL-xLΔC were mixed together to form a 1:1 complex and subsequently resolved by 
native PAGE. Full-length PUMA was then competed from the complex using BIMBH3, 
which binds with affinity similar to PUMA (Figure 3.5) but does not induce dimer 
formation (Figure 3.4C). We found that under these conditions, the PUMA-induced 
dimer persisted even when one or both binding sites were effectively replaced with 
BIMBH3 (Figure 3.6C). Therefore, the BCL-xLΔC dimer induced by PUMABH3 is stable, 
and was not detected to be in dynamic equilibrium with a monomeric complex. 
 
 
A Structure of BCL-xL∆C   
 
 X-ray crystallography was first used to confirm the oligomeric state of our 
recombinant human BCL-xLΔC prior to its co-crystallization with the PUMABH3.  BCL-
xLΔC was crystallized in the same space group and unit cell as the published BCL-xLΔC 
structure (PDB code 1R2D) (Manion et al., 2004), and the structure was determined at 
2.1 Å resolution by direct refinement. As expected, BCL-xLΔC was found to be 
monomeric and virtually identical to 1R2D with a Cα root mean square deviation 
(RMSD) of 0.5 Å (Figure 3.7A). Also consistent with previous BCL-xLΔC structural 
studies, the protein comprises eight α-helices (α1- α8) and contains a 56 amino acid 
unstructured loop (residues 24-80) located between α1 and α2 for which there was no 
discernable electron density  (Manion et al., 2004; Muchmore et al., 1996b).  
 
 
The Structure of the BCL-xL∆C⋅PUMABH3 Complex 
 
BCL-xLΔC was then co-crystallized with a 25 amino acid PUMABH3 (Table 3.1), 
and the structure was determined to 2.9 Å resolution by molecular replacement using our 
2.1 Å monomeric BCL-xL∆C structure as the search model. The asymmetric unit 
contained two monomers, molecules ‘A’ and ‘B’, but the electron density for molecule A 
was far superior. Density for the entire BCL-xLΔC molecule A was visible and readily 
interpretable apart from the unstructured loop, whereas density for molecule B was very 
poor for residues 101-121 and 132-133. Our structural conclusions on the complex are 
therefore largely based on molecule A. Clear electron density for the PUMABH3 was 
visible in the initial 2fo-fc map within the hydrophobic groove of molecule A formed by 
the BH1, BH2, and BH3 regions of BCL-xL∆C.  This region was previously shown to 
bind BH3 domain peptides (Petros et al., 2000; Sattler et al., 1997), and the density 
corresponded to amino acids 71-90 of the PUMA BH3 domain in which residues adopt 
an α-helical conformation.  The peptide binding groove of molecule B was not visible in 
the electron density map (residues 101-121) and it was not possible to discern whether 
PUMABH3 was bound to this molecule. 
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Figure 3.6 The PUMA-induced BCL-xL Dimer Shows No Signs of Dynamic 
Equilibrium. 
(A) The PUMABH3-induced BCL-xL dimer remained intact following injection of 20 µg 
of the complex (cyan trace). The diluted complex was collected, re-injected, and still 
migrated as a single species with an identical retention volume as the initial run (red 
trace). BCL-xL monomer (diluted to match the absorbance of the re-injected PUMABH3-
induced BCL-xL dimer) was also run for comparison (blue trace). (B) Sedimentation 
equilibrium analysis of BCL-xLΔC·PUMABH3. Absorbance scans at 230 nm at 
equilibrium are plotted versus the distance from the axis of rotation. The protein was 
centrifuged in a 20 mM sodium phosphate pH 7.0, 100 mM NaCl buffer at 4 °C for at 
least 24 hr at each rotor speed of 15, 22 and 28,000 rpm. The data fit best to a single 
species model. The solid lines represent the global nonlinear least squares best-fit of all 
the data sets to a single species model with a molecular weight of 50.1 kDa (theoretical 
molecular weight = 53.3 kDa). For clarity only data for the smallest loading protein 
concentration of 0.19 μM are shown. The RMSD for the fits were between 0.0013 - 
0.0026 absorbance units. (C) BIMBH3 displacement of PUMA from PUMA-induced 
BCL-xL dimer. Indicated concentrations of BIMBH3 were added to BCL-xLΔC or the 
PUMA-induced BCL-xLΔC dimer. Titrations were analyzed by native PAGE followed 
by western blot to detect BCL-xL oligomeric status. 
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Figure 3.7 Structures of BCL-xLΔC and the BCL-xLΔC·PUMABH3 Complex. 
(A) The crystal structure of monomeric, human BCL-xLΔC solved at 2.1 Å resolution. 
Helices alpha 1 (α1), α2 and α5 are green (left) or slate (right). In both panels, α3, α4 and 
α6-α8 are yellow, cyan and pink, respectively. (B) Crystal structure of the 2:2 PUMABH3-
induced BCL-xLΔC dimer solved to 2.9 Å resolution. The helices in the two subunits of 
the BCL-xLΔC dimer are labeled α1-α8 and α1'-α8', respectively. α1, α2 and α5 are green 
(left side of molecule) or slate (right side of molecule); α3, α4 and α6-α8 are yellow, cyan 
and pink, respectively; PUMABH3 is magenta. 
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Within the crystal, molecules A and B each created crystallographic dimers 
around 2-fold axes, and the A dimer was well resolved due to its superior electron 
density. Interestingly, additional unexpected electron density was observed in the initial 
composite omit map extending out from helix α5 rather than forming the reverse turn 
(residues 157-160) that links α5 to α6 and results in a chain reversal in the monomeric 
BCL-xL∆C core structure. After model building and refinement, it was clear that this 
region had been rearranged such that α5 and α6 formed a continuous α-helix to generate a 
domain-swapped dimer in which α6-α8 of one BCL-xL∆C molecule replaces α6'-α8' of 
the symmetry mate (Figure 3.7B). This rearrangement provided an obvious and attractive 
structural explanation for our observations that the binding of the PUMABH3 promoted 
dimerization of recombinant forms of BCL-xL (Figure 3.3, Figure 3.4, and Figure 3.6). 
Although less clear in the B molecule, the refined electron density unequivocally showed 
that the same rearrangement had taken place in both molecules of the crystal asymmetric 
unit. 
 
We performed NMR to determine if the PUMABH3-induced BCL-xL dimer is 
domain swapped in solution as seen in our crystal structure. BCL-xLΔLΔC monomer 
versus heat-induced, domain-swapped BCL-xLΔLΔC apo-dimer are distinguished by the 
hallmark positions of the W24 HN-indole and V135 methyl resonances (Denisov et al., 
2007a), and we confirmed this (Figure 3.8). While binding of PUMABH3 to pre-formed 
BCL-xLΔL∆C apo-dimers had virtually no effect on the positions of these resonances for 
the dimer, addition of PUMABH3 to BCL-xLΔL∆C monomer induced identical shifts of 
both W24 and V135 resonances, characteristic of BCL-xL domain-swapped dimer 
formation (Denisov et al., 2007a) (Figure 3.8).  
 
To further test the idea that the BCL-xL∆C dimer induced by PUMABH3 in 
solution is indeed what we observed in the crystal structure, we introduced cysteines into 
BCL-xL∆C that would be in a approximate 12 Å proximity only upon dimer formation 
(Figure 3.9A), as previously described for the alkaline pH-induced, domain-swapped 
BCL-xL∆C apo-dimer (O'Neill et al., 2006). Treatment of the mutant BCL-xL∆C 
monomers with the cross-linking agent bismaleimidohexane (BMH) produced no higher 
order structures; however upon addition of PUMABH3, cross-linking revealed dimers 
(Figure 3.9B). Similarly, introduction of cysteines designed to prevent “opening” of 
BCL-xL∆C by formation of a disulfide bond (Figure 3.9C) prevented PUMABH3 from 
inducing dimer formation in the disulfide “trapped” monomer but readily induced 
dimerization in the presence of reducing agent (Figure 3.9D). Together, these results 
strongly suggest that the BCL-xL∆C dimer induced by PUMABH3 in solution is the same 
as our crystal structure. 
 
 
Analyses of the BCL-xL∆C⋅PUMABH3 Interaction Reveal the Mechanism for 
PUMA-induced BCL-xL Dimerization of BCL-xL 
 
While the oligomeric state of the 2:2 BCL-xL∆C⋅PUMABH3 complex is strikingly 
different from the 1:1 oligomeric state of BCL-xL∆C bound to the BADBH3, BAKBH3 or   
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Figure 3.8 The BCL-xLΔC·PUMABH3 Complex Is Domain Swapped in Solution. 
Regions from 1D 1H NMR spectra showing previously assigned (Denisov et al., 2007b) 
Trp indole resonances (A) and the methyl group resonance of Val 135 (B) of 15N-BCL-
xLΔC monomer (blue), 15N-BCL-xLΔC apo-dimer (red), 15N-BCL-xLΔC apo-
dimer·PUMABH3 (green), and 15N-BCL-xLΔC monomer·PUMABH3 (magenta). Two-
dimensional (2D) 1H-15N TROSY spectra of 15N-BCL-xLΔC monomer (C), 15N-BCL-
xLΔC apo-dimer (D), 15N-BCL-xLΔC apo-dimer + PUMABH3 (E), and 15N-BCL-xLΔC 
monomer + PUMABH3 (F). Tryptophan HN-indole resonances are shown within the black 
dashed boxes. (G) Overlay of 2D spectra from (E) and (F). When a red and a green peak 
perfectly overlay, a yellow peak is produced. The observation that all resonances appear 
yellow when the individual 2D spectra (E-F) are overlaid indicates that the PUMA-
induced BCL-xL dimer prepared in solution was domain swapped as observed in the 
crystal structure. BCL-xL∆C dimer induced by PUMABH3 in solution is the same as our 
crystal structure. 
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Figure 3.9 Structure-dependent Crosslinking of the PUMA-induced BCL-xL 
Domain Swapped Dimer Reveals that PUMA-induced BCL-xL Dimerization Occurs 
via Domain Swapping. 
Two types of BCL-xLΔC cysteine mutants were created to probe the structure of the 
domain swapped dimer in solution; one type involved introduction of either an E7C or 
N175C point mutation (A) and another type involved introduction of dual mutations, 
V135C and W181C (C). (A) Domain swapped dimerization of the two BCL-xLΔC point 
mutants mixed at equimolar ratios positions these two residues in proximity for covalent 
linkage by the cross linking reagent BMH (shown in yellow). (B) Wild type BCL-xLΔC, 
BCL-xLΔC E7C, BCL-xLΔC N175C, and an equimolar ratio of BCL-xLΔC E7C and 
BCL-xLΔC N175C were either untreated or treated with BMH in the presence or absence 
of PUMABH3, and the proteins were analyzed by SDS-PAGE followed by western blot 
analysis for BCL-xL.  50% of PUMA binding-induced dimers that form contain V135C 
in one polypeptide chain and W181C in the other and are able to be crosslinked. PUMA 
does not induce dimerization of disulfide bond “trapped” BCL-xL in the absence of 
reducing agent. (C) A BCL-xLΔC mutant covalently locked in the monomeric state was 
created by introducing two cysteines, V135C and W181C, that form a solvent exposed 
disulfide bond (shown in yellow) linking the loop connecting α3 and α4 to α7. (D) The 
disulfide trapped monomer was treated with buffer or PUMABH3 in the presence or 
absence of reducing agent, and the samples were analyzed by native PAGE and 
Coomassie staining to assess BCL-xL oligomeric status. BCL-xLΔC monomer and BCL-
xLΔC apo-dimer were used as molecular weight standards. Bismaleimidohexane (BMH), 
Tris[2-carboxyethyl] phosphine (TCEP). 
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BIMBH3 domain peptides (Petros et al., 2000; Sattler et al., 1997),many of the important 
interactions between BH3 domain peptides and BCL-xL∆C were observed. PUMABH3 
bound within the surface-exposed hydrophobic groove of BCL-xL∆C, and the 
intermolecular interface was dominated by hydrophobic interactions in which I75, L79, 
R80, M2, L86 and Y90 of the PUMA peptide are particularly important (Figure 3.10). 
I75 was buried within a hydrophobic pocket formed by residues V126, L112, L108, F146 
and F105 of BCL-xL∆C. L79 and D84 are part of the conserved L-x-x-x-x-D motif (x = 
any amino acid) of the PUMABH3 (Petros et al., 2004b). L79 packed into a hydrophobic 
groove surrounded by BCL-xL∆C residues F146, F105, V126, F97, L130 and A142 
(Figure 3.10), and D84 formed hydrogen bonds with R139 and N136, respectively 
(Figure 3.10). The aliphatic α, β and γ carbons of R80 packed against L130 of BCL-
xLΔC, and the terminal guanidinium moiety formed hydrogen bonding interactions with 
E129 of BCL-xLΔC (Figure 3.10). M82 packed against residues F105, A104, Y101, and 
F97 of BCL-xL∆C and was partially solvent exposed as observed in the BCL-
xL∆C⋅BADBH3 peptide structure (Petros et al., 2000). Finally, L86 and Y90 were also 
partially exposed to solvent and packed against BCL-xL∆C residues Y101, F97, A93, 
V141, Y195 and G138; and Y195 and L194, respectively (Figure 3.10). R100 of BCL-
xL∆C formed hydrogen bonds and/or electrostatic interactions with Q89 of the PUMA 
peptide, and Y101 of BCL-xL∆C formed electrostatic interactions with D85 and the 
backbone carbonyl oxygen of M82 of the PUMA peptide (Figure 3.10). The residues of 
PUMABH3 that mediated the hydrophobic interactions with BCL-xL∆C described above 
form a hydrophobic spine primarily along one face of the α-helical structure adopted by 
the PUMABH3 (Figure 3.10). Residues along the opposite face mediated an extensive 
hydrogen bonding and electrostatic interaction network with BCL-xL∆C (Figure 3.10).  
 
The thermodynamic contributions of the key amino acids found to be important 
for the BCL-xL∆C·PUMABH3 interaction in our crystal structure were determined using 
alanine mutagenesis and a fluorescence anisotropy binding assay (Figure 3.11). The 
results were fully consistent with the structural interpretations discussed above, as 
individual mutation of PUMABH3 residues I75, L79, R80, M2, L86, and Y90 to alanine 
resulted in a decreased binding affinity for BCL-xL∆C and increased -ΔΔG values 
(Figure 3.11). 
 
Another notable feature of the BCL-xL∆C·PUMABH3 structure is that P116 from 
BCL-xL∆C, which separates α3 and α4, was markedly displaced relative to its position in 
the BCL-xL∆C monomer structure (Figure 3.12). Interestingly, this proline has been 
reported to constitute a portion of the p53 binding epitope with BCL-xL (Petros et al., 
2004a; Tomita et al., 2006). Specifically, P116 was displaced by approximately 5 Å 
relative to its position in monomeric BCL-xL∆C as well as all other previously 
determined BH3 domain peptide⋅BCL-xL∆C structures (Figure 3.12).  
 
 The conformational change centered on P116 (Figure 3.12B) was associated with 
a π-stacking interaction between the aromatic side chain of W71 from the PUMA peptide 
and the imidazole ring of H113 from BCL-xL∆C (Figure 3.12C). This interaction is 
clearly visible in the 2fo-fc electron density map (Figure 3.12D). 
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Figure 3.10 Details of the BCL-xL·PUMABH3 Interaction. 
(A) For clarity, only one side of the dimer, comprising BCL-xLΔC α1-α5 and α6'-α8' and 
one PUMABH3, is illustrated. The BCL-xL∆C hydrophobic groove is yellow, the 
remainder of the BCL-xL∆C surface is slate, and the PUMABH3 is magenta. PUMABH3 
side chains with transparent green spheres illustrate hydrophobic residues or atoms that 
pack into the BCL-xL∆C hydrophobic groove. PUMABH3 and BCL-xL∆C residues are 
indicated in red and white, respectively. Hydrogen bonds and electrostatic interactions 
are shown as white dashed lines.  (B) Re-representation of C showing BCL-xLΔC with 
the PUMABH3 removed. The hydrophobic residues and side chain atoms of BCL-xLΔC 
that interact with the hydrophobic residues of PUMABH3 are yellow. The α7'-α8' C-
terminus from the juxtaposed BCL-xLΔC molecule within the dimer is rose; α6' is not 
illustrated for clarity. 
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Figure 3.11 Verification of PUMABH3 Side Chain Interactions with BCL-xLΔC by 
Fluorescence Anisotropy. 
(A) -ΔΔG values for the indicated PUMABH3 alanine mutants binding to BCL-xLΔC. 
Error bars represent the standard deviation calculated from at least two independent 
experiments. (B) Non-linear regression plots of the fraction of the indicated PUMA 
peptide bound versus BCL-xLΔC concentration. The binding affinity and value for ΔG 
were obtained by curve fitting. Error bars and errors represent the standard deviations 
calculated from at least two independent experiments. 
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Figure 3.12 PUMA W71 Forms a π-stacking Interaction with BCL-xL H113. 
 (A) One side of the BCL-xLΔC·PUMABH3 dimer (P116 is indicated and helices α6'-α8' 
are noted in parentheses) is shown superposed onto the monomeric BCL-xLΔC structure 
(green). The binding of PUMABH3 perturbed BCL-xL∆C helices α3-α4 and influenced 
their interactions with α5-α6', which are opposite to the PUMABH3 binding site.  (B) 
Expansion of the red dashed box in A after rotation of the view by approximately 90˚ 
illustrating the position of P116 in the turn between BCL-xL∆C α3 and α4. Binding of 
the PUMABH3 resulted in an approximate 5 Ǻ displacement of BCL-xL∆C P116 (slate) 
compared to its position in the BCL-xLΔC monomer (green), BCL-xLΔC·BADBH3 
(yellow, PDB 2BZW), BCL-xLΔC·BIMBH3 (pink, PDB 1PQ1) and BCL-
xLΔLΔC·BAKBH3 (red, PDB 1BXL) structures. (C) Side chains of PUMABH3 W71 and 
BCL-xLΔC H113 formed a π-stacking interaction that is associated with an approximate 
five Ǻ displacement of BCL-xL∆C P116 as shown in B. BCL-xLΔC is slate and 
PUMABH3 is magenta. (D) 2fO-fC electron density map surrounding PUMABH3 W71 and 
BCL-xL∆C H113 contoured at 2σ.  
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That the shift in BCL-xL P116 is a consequence of the PUMA W71·BCL-xL 
H113 interaction, and thus a potential cause rather than a consequence of dimer 
formation, is supported by the observation that P116 in the alkaline pH-induced BCL-xL 
apo-dimer is not shifted relative to that in the BCL-xL monomer (O'Neill et al., 2006). 
This unique structural feature of the BCL-xL∆C⋅PUMABH3 complex altered the typical 
hydrophobic packing between the α3-α4 and α5-α6 “layers” of BCL-xL∆C that is 
observed in its complexes with other BH3 domain peptides (Figure 3.12). We 
hypothesize that disruption of this α3-α4/α5-α6 interface allows the α6-α8 structural unit 
to become dislodged from the α1-α5 core, promoting BCL-xL∆C dimerization. 
 
To directly test the influence of the PUMA W71⋅BCL-xL∆C H113 interaction on 
BCL-xL dimerization, we performed a native PAGE assay using BH3 domain peptides 
from PUMA, BAD, two PUMA-BAD chimeras in which peptide residues 1-13 and 14-25 
were exchanged (termed BAD-PUMABH3 and PUMA-BADBH3) and a PUMA BH3 
peptide in which W71 was mutated to alanine (termed PUMABH3 W71A) (Figure 3.13A). 
Addition of two molar equivalents of PUMABH3 but not BADBH3 induced BCL-xL∆C 
dimerization (Figure 3.13A). The BAD-PUMABH3 peptide (which lacks the W residue 
crucial for π-stacking with BCL-xL H113) and PUMABH3 W71A failed to induce 
dimerization of BCL-xL∆C, while the PUMA-BADBH3 peptide readily induced BCL-xL 
dimerization (Figure 3.13A). In this assay, wild type PUMA BH3 domain peptide or 
alanine point mutants were used at a concentration of 100 µM except for those alanine 
mutants (shown in Figure 3.13B enclosed within red dashed boxes) that we previously 
showed by fluorescence spectroscopy had dramatically decrease affinity for BCL-xL, 
which were used at a concentration of 800 µM to force binding through mass action. We 
further tested the role of BCL-xL∆C H113 in dimer formation. While PUMABH3 induced 
dimer formation of BCL-xL∆C, no dimerization was induced in BCL-xL∆C H113A 
(Figure 3.13C). Therefore, both PUMA W71 and BCL-xL H113 are necessary for 
PUMA-induced dimerization of BCL-xL∆C. 
 
 
PUMA W71 Is Required to Promote p53-dependent MOMP and Apoptosis 
 
We examined the consequences of the PUMA W71A mutation for binding to anti- 
apoptotic BCL-2 proteins by ITC.  While this substitution had no effect on the binding 
affinity of PUMABH3 to BCL-xL∆C or BCL-xL∆C apo-dimer (Figure 3.14A and Figure 
3.11), it increased binding affinity for the anti-apoptotic proteins BFL-1∆C and MCL-
1∆C (Figure 3.14B-C). We therefore examined the role of PUMA W71 on apoptosis in 
cells. Wild type and puma-/- MEFs were equally susceptible to apoptosis induced by TNF 
(Figure 3.15A). Introduction of PUMA or PUMABH3 W71A sensitized cells for TNF- 
induced apoptosis to an equivalent extent (Figure 3.15A). We next compared PUMA and 
PUMABH3 W71A in p53-dependent, DNA damage-induced apoptosis. In these cells,  
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Figure 3.13 PUMA-induced Dimerization of BCL-xL is Mediated Uniquely by the 
π-stacking Interaction between PUMA W71 and BCL-xL H113. 
PUMABH3 W71 was critical for BCL-xLΔC dimerization in vitro. (A) BCL-xLΔC was 
incubated with the indicated peptides and subjected to native PAGE followed by 
Coomassie staining. (B) PUMABH3, fluoresceinated-PUMABH3 (F-PUMA), or alanine 
point mutants important for interaction with BCL-xL were added to BCL-xL monomer 
and dimerization analyzed by native PAGE followed by Coomassie staining. F-
PUMABH3 peptides were those used in Figure 3.11. For those peptides displaying 
decreased affinity for BCL-xL, 800 μM of peptide was added (red boxes).The presence of 
fluorescein did not affect peptide-induced dimer formation. (C) BCL-xL H113 was 
critical for BCL-xLΔC dimerization in vitro. BCL-xLΔC and BCL-xLΔC H113A were 
incubated in the presence of PUMABH3, and dimerization was analyzed by native PAGE 
followed by Coomassie staining. BCL-xLΔC monomer and BCL-xLΔC apo-dimer were 
used as molecular weight standards (A-C). 
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Figure 3.14 The W71A Point Mutation in PUMABH3 Does Not Affect Binding to 
Other Anti-apoptotic BCL-2 Family Proteins.  
(A) The PUMABH3 binds both BCL-xLΔC monomer and BCL-xLΔC apo-dimer with 
equal affinity. ITC binding isotherms for PUMABH3 (100 μM) titrated into a solution of 
BCL-xLΔC (10 μM) (left panel) or BCL-xLΔC apo-dimer (10 μM) (right panel). ITC 
binding isotherms for PUMABH3 and PUMABH3 W133A (100 μM) titrated into a solution of 
BFL-1ΔC (10 μM) (B) or MCL-1ΔC (10 μM) (C). 
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Figure 3.15 PUMA W71 Specifically Promotes DNA Damage-induced Apoptosis. 
(A) Wild type and puma-/- MEFs were transiently transfected with pCMVneoBam, 
pCMV5neoBam-FLAG-PUMA or pCMV5neoBam-FLAG-PUMA W71A and allowed to 
recover for 24 h, treated with TNF (0, 5 & 10 ng/ml) and cycloheximide (10 µg/ml) for 6 
hours and analyzed by AnnexinV-PE staining and flow cytometry for apoptosis. US9-
GFP was co-transfected and only GFP positive cells were analyzed. (B) Wild type, p53-/- 
and puma-/- MEFs were treated with UV irradiation (0, 2.5 & 5 mJ/cm2) and analyzed 24 
hours later by AnnexinV-PE staining and flow cytometry for apoptosis. (C) puma-/- MEFs 
were transiently transfected with pCMVneoBam, pCMVneoBam-FLAG-PUMA or 
pCMVneoBam-FLAG-PUMA W71A (PUMAW71A), recovered for 24 h, treated with UV 
irradiation (0, 2.5 & 5 mJ/cm2) and analyzed 24 hours later by AnnexinV-PE staining and 
flow cytometry for apoptosis. US9-GFP was co-transfected, and only GFP positive cells 
were analyzed. Error bars represent the standard deviation calculated from at least three 
independent experiments (A-C). 
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apoptosis required both p53 and PUMA (Figure 3.15B), as described (Jeffers et al., 
2003; Villunger et al., 2003). Strikingly, while introduction of PUMA ino puma-/- cells 
effectively restored sensitivity to UV-induced apoptosis, introduction of PUMABH3 W71A 
did not (Figure 3.15C). Consistent with our finding that PUMABH3 and PUMABH3 W71A  
bind to BCL-xL equivalently (Figure 3.11), co-immunoprecipitation of ectopically 
expressed PUMA or PUMABH3 W71A co-precipitated endogenous BCL-xL in both cases 
(Figure 3.16). Intriguingly, only PUMA W71A but not PUMA co-precipitated cytosolic 
p53 in cells exposed to UV (Figure 3.16). We will return to this observation below.  
 
We then examined the effects of PUMA on the oligomeric state of BCL-xL in 
cells. Wild type or puma-/- MEFs were subjected to UV irradiation, which induces PUMA 
expression, and endogenous BCL-xL was analyzed by native PAGE and western analysis 
(Figure 3.17). As controls, we compared recombinant BCL-xLΔC monomer, BCL-xLΔC 
apo-dimer, and BCL-xLΔC·PUMA dimer. Endogenous BCL-xL in wild type MEFs 
exposed to UV appeared as a higher order, PUMA-bound dimer, while in puma-/- cells, 
BCL-xL remained monomeric (compare left and right panels, Figure 3.17). Ectopic 
expression of PUMA in puma-/- cells similarly resulted in the generation of the higher 
order, PUMA-bound BCL-xL dimer, while PUMA W71A bound to BCL-xL with a 1:1 
ratio (Figure 3.17). 
 
Since PUMA occupies the same binding groove in BCL-xL that is bound by all 
other BH3-only proteins, it was not obvious what effect the specific induction of BCL-xL 
dimerization might have on apoptotic signaling and cell fate.  We therefore interrogated 
protein·protein interactions that might be affected by such dimerization. It has been  
previously shown that p53UVIP is bound by BCL-xL, and that disruption of the BCL-
xL·p53UVIP complex by PUMA releases p53UVIP to activate BAX and induce MOMP in 
isolated mitochondria, as detected by the release of cytochrome c (Chipuk et al., 2005a).  
Mitochondria from poly-dIdC-treated MxCre bak-/- baxf/- mice (referred hereafter as bak-/-
bax-/-) did not undergo MOMP in response to C8-BID, p53UVIP, PUMA or BAX ; 
however,bax -/-bax-/- mitochondria released cytochrome c when exposed to BAX plus C8-
BID or p53UVIP (but not PUMA or PUMABH3) (Figure 3.18), as previously described 
(Chipuk et al., 2008). We then compared the ability of PUMA or PUMABH3 and other de-
repressor BH3 domain peptides to disrupt a BCL-xLΔC·p53UVIP complex and induce 
BAX-dependent MOMP (Figure 3.19). Bak-/-bax-/- mitochondria were incubated with 
BAX plus BCL-xLΔC·p53UVIP.  In the presence of PUMA or PUMABH3, cytochrome c 
release occurred, and p53 did not co-precipitate with BCL-xLΔC indicating it had been 
released from BCL-xL (Figure 3.19A). In contrast, none of the other de-repressor BH3 
domain peptides disrupted the BCL-xLΔC·p53UVIP complex or promoted BAX-dependent 
MOMP (Figure 3.19A). Similarly, failed to disrupt the BCL-xLΔC·p53UVIP (Figure 
3.19B). The direct activator BH3-only peptides were not tested as in Figure 3.19A, as 
these BH3 domain peptides directly promote BAX-dependent MOMP (Kuwana et al., 
2005). As mentioned above, all BH3 domain peptides were capable of binding to BCL-
xL, as determined by ITC (Figure 3.5). Thus, the unique ability of PUMA to disrupt the 
BCL-xL·p53UVIP complex could not be ascribed to differences in affinity between PUMA 
and all other BH3-only proteins, as some of these BH3 domain peptides exhibited 
binding affinity similar to or greater than that of PUMABH3 (e.g., BIMBH3 and BADBH3). 
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Figure 3.16 P53 and PUMA Bind Different Solvent-exposed Surfaces on BCL-xL. 
Lysates from Figure 3.15C above were subjected to co-immunoprecipitation with anti-
FLAG and analyzed by SDS-PAGE and western blot for FLAG-PUMA (wild type or 
W71A), BCL-xL and p53. 
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Figure 3.17 PUMA Induces BCL-xL Dimerization in Cells. 
Wild type and puma-/- MEFs (mouse embryonic fibroblasts) were treated with UV 
irradiation (2.5 mJ/cm2); and puma-/- MEFs were transiently transfected with 
pCMVneoBam-FLAG-PUMA or pCMVneoBam-FLAG-PUMAW133A. Lysates were 
subjected to native-PAGE and western blot analysis for BCL-xL dimerizationand PUMA 
association. BCL-xLΔC monomer, BCL-xLΔC apo-dimer and BCL-xLΔC PUMA-dimer 
were used as native PAGE controls. 
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Figure 3.18 C8-BID and p53 Exhibit Direct Activation of BAX and Induction of 
MOMP, whereas PUMA Does Not. 
Purified mitochondria from bak-/-bax-/- liver were treated with p53UVIP (10 nM) or C8-
BID (10 nM) in the presence or absence of BAX (20 nM) for one hr at 37 ºC before 
fractionation, SDS-PAGE and western blot analyses for cytochrome c. C8-BID was a 
positive control for direct activator function. 
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Figure 3.19 PUMA and PUMABH3 Uniquely Release p53UVIP from BCL-xL∆C. 
(A) 10 nM complexes of BCL-xLΔC·p53UVIP were combined with bak-/-bax-/- liver 
mitochondria in the presence of BAX (20 nM) and indicated de-repressor BH3 domain 
peptides or PUMA (100 nM) for one hour at 37 ºC before fractionation, SDS-PAGE and 
western blot analyses for p53UVIP, BCL-xLΔC and cytochrome c. (B) 10 nM complexes 
of BCL-xLΔC·p53UVIP were combined with PUMABH3 (10, 50, and 100 nM) or the 
indicated direct activator BH3 domain peptides (10, 50, and 100 nM) and BCL-xL was 
then isolated by affinity chromatography. Associated p53 and BCL-xL were detected by 
western blot. 
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We next investigated the role of PUMA W71 in de-repression of C8-BID or 
p53UVIP from BCL-xL∆C to promote BAX activation and MOMP.  Bak-/-bax-/- 
mitochondria underwent complete cytochrome c release when treated with BAX and 
either C8-BID or p53UVIP, and BCL-xL∆C inhibited the release induced by both direct 
activator proteins (Figure 3.20). PUMA protein, PUMABH3, PUMABH3 W71A, PUMA-
BADBH3 and BADBH3 all failed to exhibit direct activator activity when added with BAX 
(Figure 3.20A); however, all of these completely de-repressed C8-BID from BCL-xL∆C 
to induce cytochrome c release (Figure 3.20A). The ability of the chimeric peptides to 
displace C8-BID from BCL-xLΔC confirmed that these peptides bound within the 
hydrophobic groove of BCL-xLΔC similarly to other BH3 domain peptides.  In contrast, 
PUMA protein, PUMABH3 and PUMA-BADBH3 promoted p53UVIP-dependent cytochrome 
c release, but PUMABH3 W71A and BADBH3 did not (Figure 3.20B); therefore, PUMA 
W71 was essential for dissociation of p53UVIP from BCL-xL∆C. 
  
Both PUMA-mediated BCL-xL dimerization and p53UVIP de-repression required 
the presence of W71 in PUMA, and therefore it was likely that PUMA-induced BCL-xL 
dimerization promoted p53-dependent apoptosis by disrupting the sequestration of 
cytosolic p53 by BCL-xL. We tested this idea by examining the effects of PUMA on 
dimerization of BCL-xLΔC under these conditions. As in our previous experiments, 
p53UVIP and BAX cooperated to promote cytochrome c release that was inhibited by 
BCL-xL∆C monomer (Figure 3.21A). Addition of PUMA or PUMABH3 disrupted the 
p53UVIP⋅BCL-xL∆C complex to induce cytochrome c release (Figure 3.20A). BADBH3 
failed to de-repress this complex to promote cytochrome c release and BCL-xLΔC apo-
dimer did not inhibit p53UVIP-induced, BAX-mediated cytochrome c release (Figure 
3.21A). Native PAGE and western blot analysis following the above treatments revealed 
that PUMA protein and PUMABH3 induced dimerization of BCL-xL∆C monomers within 
the MOMP reactions, and this effect correlated with cytochrome c release (Figure 3.21A 
-B).  
 
 
Dimeric BCL-xL∆C Does Not Inhibit p53-dependent MOMP 
 
Based on our structural findings, we hypothesized that PUMA-induced 
dimerization of BCL-xL provides a mechanism for modulating the association between 
cytoplasmic p53 and BCL-xL, and therefore the direct activator function of cytoplasmic 
p53. To test this hypothesis, co-immunoprecipitation experiments were performed. BCL- 
xLΔC monomer or BCL-xL∆C apo-dimer were incubated with baculovirus-expressed, 
full-length human p53 (p53Bac), and this complex was co-immunoprecipitated with 
antibodies against either p53 or BCL-xL∆C, followed by SDS-PAGE and western blot 
analysis (Figure 3.22A-B). In all cases, BCL-xLΔC monomer bound to p53Bac, consistent 
with earlier results using endogenous BCL-xL and stress-induced p53 (Chipuk et al., 
2005b; Chipuk et al., 2004). In contrast, BCL-xLΔC apo-dimer did not associate 
withp53Bac (Figure 3.22A-B). Further, the interaction of BCL-xLΔC monomer or BCL-
xLΔC apo-dimer with p53Bac was quantitatively analyzed in solution using ITC. BCL-
xLΔC monomer bound to p53 with a Kd value of 254 nM (Figure 3.22C). In contrast,   
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Figure 3.20 PUMA W71 Is Critical for De-repression of p53 but Not C8-BID from 
BCL-xL. 
(A) 10 nM complexes of BCL-xLΔC·C8-BID were combined with bak-/-bax-/- liver 
mitochondria in the presence of BAX (20 nM) and indicated de-repressor BH3 domain 
peptides (1 μM) or PUMA (100 nM) for one hour at 37 ºC before fractionation, SDS-
PAGE and western blot analyses for cytochrome c. (B) 10 nM complexes of BCL-
xLΔC·p53UVIP were combined with bak-/-bax-/- liver mitochondria in the presence of BAX 
(20 nM) and indicated de-repressor BH3 domain peptides (1 μM) or PUMA (100 nM) for 
one hour at 37 ºC before fractionation, SDS-PAGE and western blot analyses for 
cytochrome c. 
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Figure 3.21 PUMA-Induced BCL-xL∆C Dimerization Correlates with p53UVIP-
dependent BAX Activation and Subsequent Cytochrome c Release. 
(A) Purified mitochondria from bak-/-bax-/- liver were treated with the indicated proteins 
and/or BH3 domain peptides before fractionation, SDS-PAGE and western blot analyses 
for cytochrome c.  (B) Supernatants from the indicated reactions in (A) were subjected to 
native PAGE and western blot analyses for BCL-xL∆C and PUMA. 
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Figure 3.22 Only Monomeric BCL-xL∆C Binds and Inhibits p53. 
(A) Baculovirus-expressed p53 (100 nM) was incubated with BCL-xLΔC monomer or 
BCL-xLΔC apo-dimer (100 nM), immunoprecipitated with antibodies against p53UVIP 
(left) or BCL-xL∆C (right) and subjected to SDS-PAGE and western blot analysis for 
p53UVIP or BCL-xLΔC.  Immunoprecipitation with a mouse IgG was the negative control. 
(B) ITC binding isotherms for BCL-xL∆C monomer and BCL-xLΔC apo-dimer (250 
μM) titrated into a solution of p53Bac (10 μM). 
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no association of BCL-xLΔC apo-dimer with p53Bac was detected (Figure 3.22C). 
Together, these co-immunoprecipitation and ITC data demonstrate that BCL-xLΔC 
monomer and p53 directly interact with high affinity whereas BCL-xLΔC apo-dimer is 
unable to interact with p53. 
 
We next compared the ability of BCL-xLΔC monomer and BCL-xLΔC apo-dimer 
to regulate p53-dependent BAX activation and MOMP. Bak-/-bax-/- mitochondria 
underwent complete cytochrome c release when treated with p53UVIP and BAX (Figure 
3.23A). This release was fully inhibited by the addition of BCL-xL∆C monomer but not 
BCL-xLΔC apo-dimer (Figure 3.23A). In contrast, both BCL-xL∆C monomer and BCL-
xLΔC apo-dimer inhibited C8-BID-induced cytochrome c release (Figure 3.23B). These 
reults were expected, as both BCL-xL monomer and apo-dimer possess free BH3 binding 
grooves, as demonstrated by their similar ability to bind PUMABH3 and previous 
structural analyses (O'Neill et al., 2006), and therefore can sequester C8-BID to prevent 
MOMP. Therefore, consistent with the binding results shown in Figure 3.22, while BCL-
xL∆C monomer can bind and inhibit cytosolic p53, BCL-xL∆C apo-dimer lacks this 
function Figure 3.23A. Our earlier observation that p53 was co-immunoprecipitated in a 
ternary complex with PUMA W71A and BCL-xL (Figure 3.16), in which BCL-xL fails 
to dimerize (Figure 3.17), further suggests that p53 and PUMA bind to different surfaces 
on BCL-xL, consistent with previous results (Petros et al., 2004a; Sot et al., 2007; Tomita 
et al., 2006). 
 
We next utilized a novel cellular model system to examine the function of BCL-
xL monomer, BCL-xL∆C apo-dimer and BCL-xL∆C PUMA-dimer. The breast 
adenocarcinoma cell line, MCF7 (which endogenously expresses wild type p53), was 
generated to stably express the second mitochondria-derived activator of caspases fused 
to green fluorescent protein (MCF7 SMAC-GFP).  Following MOMP, SMAC-GFP is 
released from the mitochondrial intermembrane space into the cytoplasm where it is 
rapidly degraded by the proteasome; this allows for a high signal to noise ratio between 
pre- and post-MOMP detection of SMAC-GFP (Munoz-Pinedo et al., 2006).  MCF7 
SMAC-GFP cells exhibit punctate mitochondrial localization of SMAC-GFP, and 
microinjection of C8-BID (Texas Red dextran was added to all proteins to indicate 
microinjected cells) promoted SMAC-GFP release and degradation as shown by the loss 
of GFP fluorescence (Figure 3.24). C8-BID-induced MOMP was blocked by co-
microinjection of either BCL-xL∆C monomer or BCL-xLΔC apo-dimer, both of which 
have free BH3 binding grooves (Figure 3.24). 
 
To investigate endogenous direct activator BH3-only protein function, MCF7 
SMAC-GFP cells were treated with TNF and cycloheximide, which requires C8-BID to 
promote MOMP and apoptosis (Rubin et al., 1988) (Figure 3.24). In this scenario, 
SMAC-GFP was also released and degraded, and this release was blocked by 
microinjection of either BCL-xL∆C monomer or BCL-xL∆C apo-dimer (Figure 3.24). 
This pattern of SMAC-GFP release parallels that observed for cytochrome c using 
isolated mitochondria, demonstrating that the mechanistic implications of BCL-xL 
dimerization are equivalent in the two types of assays. 
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Figure 3.23 BCL-xL Monomer and BCL-xLΔC Apo-dimer Differentially Regulate 
p53UVIP and C8-BID-induced Cytochrome c Release. 
Purified mitochondria from bak-/-bax-/- (A) or C57Bl/6 (B) liver were treated with 
indicated proteins for one hour at 37 ºC before fractionation, SDS-PAGE and western 
blot analysis for cytochrome c. 
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Figure 3.24 BCL-xL Monomer and BCL-xLΔC Apo-dimer Differentially Regulate 
TNF and UV-induced MOMP. 
MCF7 SMAC-GFP cells were microinjected with indicated BCL-xL∆C variants 
(intracellular concentration varied from 0.47 – 2.35 nM) prior to treatment with TNF and 
cycloheximide (2.5 ng/ml and 20 µg/ml, respectively or 40 mJ/cm2 UV. Texas Red 
dextran was added to the protein solution to identify microinjected cells. Cells were 
imaged 5 h after apoptotic stimulation. MOMP was determined by the loss of SMAC-
GFP fluorescence. The percentages of microinjected cells with a loss of SMAC-GFP 
fluorescence are indicated and represent results from at least 200 cells. 
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The cellular implications of BCL-xL dimerization vis a vis DNA damage-induced 
cytosolic p53 function were investigated using MCF7 SMAC-GFP cells treated with 
ultraviolet (UV) radiation (Figure 3.24) UV treatment of the MCF7 SMAC-GFP cells 
induced MOMP as measured by the loss of SMAC-GFP fluorescence, which was 
inhibited by BCL-xL∆C monomer (Figure 3.24). These results paralleled those showing 
that dimeric forms of BCL-xL failed to bind p53 and to inhibit p53 direct activator 
function, suggesting strongly that UV-induced MOMP was dependent upon cytosolic 
p53.  In contrast, the ability of BCL-xL to modulate BH3-only protein direct activator 
function depended not upon its oligomeric state but rather upon whether its BH3 binding 
groove was unoccupied (e.g. not bound by PUMA). 
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CHAPTER 4.    DISCUSSION 
 
 
Our multidisciplinary studies demonstrate that PUMA induces BCL-xL 
dimerization via domain swapping, and that this unprecedented signaling mechanism 
disrupts the interaction between BCL-xL and cytosolic p53, resulting in MOMP and 
apoptosis. Mutation of W71 in PUMA, required for induction of BCL-xL dimerization, to 
alanine did not decrease the affinity of PUMABH3 for anti-apoptotic BCL-2 family 
proteins including BCL-xL, MCL-1, and BFL-1 (Figure 3.14); BCL-2 was not examined 
in this context, due to difficulties in producing the protein for ITC measurements).  
Further, PUMABH3 W71A behaved identically to PUMA in sensitizing cells for TNF-
induced apoptosis, presumably because both effectively inhibited binding of anti-
apoptotic BCL-2 proteins to the active form of BID induced in this pathway.  UV-
induced expression of endogenous PUMA or ectopic expression of wild type PUMA 
induced dimerization of endogenous BCL-xL, which was not observed in UV-treated 
puma-/- cells or upon expression of PUMABH3 W71A.  It was previously shown that ectopic 
expression of PUMA sensitizes for UV-induced apoptosis only in cells expressing p53, 
and that this disrupts the binding of BCL-xL to cytosolic p53 (Chipuk et al., 2005a).  The 
finding that PUMA but not PUMABH3 W71A sensitized cells for p53-dependent cell death 
suggested that BCL-xL dimerization and not obstruction of the BH3-binding groove is 
responsible for this effect.  Accordingly, we found that BCL-xL apo-dimer effectively 
bound C8-BID and, accordingly, inhibited TNF-induced MOMP in cells; however, BCL-
xL apo-dimer failed to bind to p53 and did not inhibit UV-induced MOMP.  Consistent 
with these observations, PUMABH3 W71A but not PUMA co-precipitated with both BCL-
xL and p53.  Therefore, one way in which PUMA-induced BCL-xL dimerization 
mediates apoptotic signaling is by affecting interactions with cytosolic p53 to control the 
activation of BAX; however, we do not preclude that such a dramatic structural change 
will affect other functions of BCL-xL. 
 
The BCL-xL·p53 binding interface has been defined in several studies using 
mutagenesis, NMR chemical shift perturbation, and other biophysical techniques mapped 
the p53 binding epitope predominantly to residues that do not overlap with the canonical 
BH3 domain binding groove (Chipuk et al., 2004; Mihara et al., 2003; Petros et al., 
2004a; Sot et al., 2007; Tomita et al., 2006) (Figure 4.1A). Based on the results of these 
previous studies regarding the BCL-xL residues that interact with p53, we propose that 
BCL-xL dimerization results in burial of the p53-binding epitope (Figure 4.1B). This 
occlusion model, in which dimerization abolishes a portion of the surface present on 
BCL-xL monomers, possibly explains our observations based on ITC experiments that 
p53 was able to bind monomeric BCL-xL with high affinity (Kd = 254 nM) but was 
unable to bind BCL-xL apo-dimers. However, the details of the BCL-xL·p53 interaction 
remain elusive, as a high resolution structure for the BCL-xL·p53 complex has yet to be 
determined. 
 
The specific signaling mechanism that regulates the pro-apoptotic activity of 
cytosolic p53 relies upon the unique ability of PUMA binding to induce BCL-xL 
dimerization.  How does PUMA uniquely trigger BCL-xL dimerization?  Past studies  
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Figure 4.1 PUMA-induced Dimerization of BCL-xL Releases p53 via Burial of 
the p53 Binding Epitope.  
(A). Residues shown by NMR chemical shift perturbation studies to be located at the 
BCL-xL·p53 interface are colored yellow. (B) Surface representation of the PUMABH3-
induced BCL-xL dimer. When compared with panel (A), the p53 binding surface of 
BCL-xL is upon Dimer Formation p53 DNA binding domain (p53DBD) is grey, BCL-xL 
is pink, and PUMABH3 is slate.  
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have shown that the structure of the BH3-binding groove of monomeric BCL-xLΔC 
undergoes subtle but distinct conformational changes upon binding various BH3 domain 
peptides (Liu et al., 2003). Analysis of BCL-xL·PUMABH3 interactions within the 
symmetric BCL-xL dimer provided insights into the mechanism of dimerization.  A 
unique feature of the BCL-xL·PUMABH3 complex discussed earlier is the π-stacking 
interaction between H113 of BCL-xL and W71 of PUMA, which alters the conformation 
of the turn connecting helices α3 and α4 relative to that observed in other BCL-xL·BH3 
peptide complexes (O'Neill et al., 2006). These interactions are enabled by other notable 
structural changes which occur within α3, which comprises 3 helical turns in the BCL-
xLΔC monomer. PUMABH3 binding-induced extension of the C-terminal end of α2 and 
melting of the three helical turns of α3 leaving a single helical turn which optimally 
positions BCL-xL residue H113 for π-stacking with W71 of the PUMABH3. Binding of 
PUMABH3 also caused the N-terminal region of BCL-xL α4 to translate toward the bound 
BH3 ligand to facilitate protein·ligand interactions, whereas the C-terminal end of α4 
pivoted outward, widening the BH3 domain binding groove. We propose that similar 
binding-induced structural rearrangements, mediated partly by the BCL-xL H113·PUMA 
W71 interaction that is unique among BCL-xL·BH3 domain peptide complexes, occur 
when PUMA binds to monomeric BCL-xL and that they transiently trigger 
disengagement of helices α6-α8 from the α1-α5 helical BC core and ultimately BCL-xL 
dimerization. 
 
It has previously been reported that several BH3-only proteins (e.g., BAD, BIM, 
and BMF) are IDPs (Hinds et al., 2006). Using CD and NMR spectroscopy we similarly 
found that full-length human PUMA is an IUP, devoid of tertiary or quaternary structure. 
Far-UV CD spectropolarimetry revealed nascent helicity within the PUMA polypeptide 
that was localized within the BH3 domain. Interestingly, the amount of nascent helical 
secondary structure present in full-length PUMA is nearly identical to that observed for 
the 25 amino acid PUMABH3, suggesting that sequences flanking the PUMA BH3 domain 
do not significantly stabilize BH3 domain helicity through helical end effects. Many IUPs 
function by folding upon binding their biological targets with the dynamic and largely 
disordered free state often exhibiting partially populated structural features that are 
observed to be fully populated in the bound-state (e.g., p27Kip1) (Lacy et al., 2004; 
Sivakolundu et al., 2005). 
  
The nascent α-helix observed within the BH3 domain of PUMA is induced to 
fully fold upon binding to the hydrophobic groove of BCL-xLΔC). The PUMA BH3 
domain adopts generally similar conformations when bound to BCL-2 family proteins, 
including BCL-xL (as shown herein), MCL-1 (Day et al., 2008) and BFL-1 (Smits et al., 
2008). However, while many interactions between PUMA and these highly related 
proteins are similar among these three complexes, we noted several differences.  For 
example, Y90 of PUMA packs in hydrophobic pockets of MCL-1 and BFL-1 in the same 
conformation relative to the axis of the PUMABH3 α-helix (Figure 4.2). In contrast, Y90 
packs into a pocket on the opposite side of the BH3 binding groove in the BCL-
xLΔC·PUMABH3 complex. Similar binding promiscuity is observed for W71 of the 
PUMABH3 that, upon binding to BCL-xL, is critical for BCL-xL dimerization and release 
of p53.  This residue exhibits the same conformation and limited interactions with polar  
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Figure 4.2 Structural Comparison of BCL-xLΔC·PUMABH3, MCL-
1ΔC·PUMABH3, and BFL-1ΔC·PUMABH3 Complexes.  
W71 and Y90 side chains (shown in black) of PUMABH3 showed drastically different 
positions within the BCL-xL·PUMABH3, MCL-1·PUMABH3 (PDB ID:2ROC) complexes., 
and BFL-1·PUMABH3 (PDB ID:2VOF) complexes. BCL-xL, MCL-1, and BFL-1 are 
slate, yellow, and green, respectively. PUMABH3 is magenta. 
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and hydrophobic moieties on the surfaces of MCL-1 and BFL-1 (Figure 4.2). However, 
through rotation of the χ1 torsion angle, W71 interacts favorably with BCL-xLΔC H113 
through π-stacking interactions (Figure 4.2). 
 
IDPs often interact with their targets through short, linear motifs (Fuxreiter et al., 
2007; Vacic et al., 2007). For PUMA, a protein of 193 residues (α isoform) or 131 
residues (β isoform), the 25 residue BH3 domain peptide appears to be necessary and 
sufficient for regulation of the BCL-2 protein family.  The intrinsic flexibility of this BH3 
domain provides the potential for adaptive binding in distinct conformations depending 
upon the structural context (e.g., binding to BCL-xL, BFL-1 or MCL-1) which can 
produce dramatically different biological outcomes. This structural plasticity allows 
PUMA to play multiple roles in regulating BCL-2 family proteins. First, PUMA binds 
tightly to the BH3 binding grooves of the entire BCL-2 repertoire (Chen et al., 2005), 
displacing more weakly bound BH3-only proteins, including the direct activators, BID 
and BIM; this function enables PUMA to broadly regulate apoptosis through mechanisms 
termed de-repression/sensitization, described above in Chapter 1. Second, PUMA, 
through the unique, binding-induced structural changes discussed above, induces BCL-
xL dimerization; this function specifically mediates UV-induced, p53-dependent MOMP 
and apoptosis. It is fascinating that, while the PUMA BH3 domain conserves many 
sequence features common to BH3 domains of other BH3-only proteins, amino acid 
differences at just a few positions within this domain (e.g., position 71) enable PUMA to 
function as both a general sensitizer and de-repressor of direct activator BH3-only 
proteins and a specific modulator of cytosolic p53-dependent apoptosis. 
 
Protein oligomerization via domain swapping is one means by which highly 
efficient protein interaction networks have evolved (Liu and Eisenberg, 2002).  The 
physiological relevance of dimerization via domain-swapping has been shown in proteins 
such as diphtheria toxin, which undergoes ligand-induced dimerization via domain 
swapping upon binding its receptor at physiologic pH (Louie et al., 1997). Interestingly, 
the structures of BCL-xL and diphtheria toxin are strikingly similar despite limited 
sequence homology (Muchmore et al., 1996b). Regarding BCL-xL dimerization via 
domain swapping, there is a substantial energy difference between the “closed” and 
“open” monomeric forms (e.g., with helices α6-α8 dislodged from the α1- α5 core), 
which constitutes an energy barrier for BCL-xL dimerization due to the need to disrupt 
many favorable packing interactions to form the “open” conformer (Liu and Eisenberg, 
2002). Once generated, two “open” BCL-xL monomers interact to form the domain-
swapped dimer. This energy barrier can be reduced by exposure of BCL-xL to non-
physiological extremes of pH (O'Neill et al., 2006) or heat (Denisov et al., 2007a).  
 
In the present study, we identified a means by which BCL-xL domain swap 
dimerization occurs under physiologically relevant conditions as a result of PUMA or 
PUMABH3 binding. We propose that alteration of hydrophobic packing between the α3- 
α4 and α5-α6 “layers” of monomeric BCL-xL due to specific structural rearrangements 
imposed by PUMA binding, in which the BCL-xL H113·PUMA W71 interaction 
discussed above is critical, decreases the energy barrier, triggering transient opening and 
dimerization.  We have observed that PUMABH3-induced dimerization does not exhibit a  
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dynamic, reversible equilibrium. This implies that the energy barrier for the reverse 
process (dimer to monomer) is large, most likely due to the favorability of the new 
interface which is formed upon rearrangement of the strained reverse turn in the BCL-xL 
monomer (O'Neill et al., 2006) into two side by side anti-parallel helices in the 
PUMABH3-induced BCL-xL dimer. The dead-end nature of this signaling mechanism, 
with PUMA triggering irreversible BCL-xL dimerization, is compatible with the 
biological outcome of the signal itself: to trigger MOMP following DNA damage and 
ultimately cell death.   While the exact mechanism(s) of BAK and BAX oligomerization 
have yet to be resolved, our data for BCL-xL dimerization by domain swapping raises the 
interesting possibility that domain swapping might play a role in the formation BAK 
and/or BAX oligomers following direct activator stimulation, as previously hypothesized 
(Leber et al., 2007). 
 
The failure of PUMABH3 W71A to promote p53-dependent apoptosis might be due 
to an effect of this substitution on the affinity of PUMA for anti-apoptotic BCL-2 
proteins.  However, we found that mutation of W71 did not affect affinity for BCL-xL, 
and slightly increased affinity for MCL-1 and BFL-1.  The ability of PUMABH3 W71A to 
promote TNF-induced apoptosis (which is p53 independent) and of the PUMABH3 W71A 
and BAD-PUMABH3 peptides to disrupt the BCL-xΔC·C8-BID complex to promote 
MOMP is similarly inconsistent with a general defect in the de-repressor activity of 
PUMABH3 W71A. 
 
Unlike BCL-xL, neither BCL-2 nor MCL-1 undergoes dimerization upon 
interaction with PUMA.  Both BCL-2 (Tomita et al., 2006) and MCL-1 (Leu et al., 2004) 
reportedly bind to cytosolic p53, but the affinities and regulation of these interactions 
versus those with BCL-xL are not yet known. In cells lacking PUMA (e.g. puma-/- MEFs 
and HCT116 PUMA-/- cells), immunoprecipitation of BCL-xL following DNA damage 
removed all available cytosolic p53 (Chipuk et al., 2005b), and therefore the regulation of 
p53 by PUMA-induced dimerization of BCL-xL is likely to be physiologically important.  
However, the situation is potentially more complex, as the interaction of PUMA with all 
of the anti-apoptotic BCL-2 proteins prevents their association with other pro-apoptotic 
BCL-2 proteins (Chen et al., 2005; Uren et al., 2007; Willis et al., 2007). Further analysis 
comparing the anti-apoptotic effects of BCL-xL versus BCL-2 and MCL-1 in the context 
of p53-dependent apoptosis will continue to reveal the mechanisms of action for the 
BCL-2 family and MOMP. 
 
 
A PUMA BH3 Mimetic for Cancer Treatment 
  
Cancer research worldwide has one principal objective: to find a cure for cancer. 
As overly simplistic and obvious as this goal may at first sound, being that each 
neoplastic subtype is born forth from an amalgam of spontaneous random gene mutations 
that by pure chance allow for clonal selection, numerous studies within the last decade 
have unveiled a phenomenon based on principles known for years. Most, if not all, 
cancers likely have an Achilles’ heel (Green and Evan, 2002) (Letai, 2008). Ironically, 
this Achilles’ heel is based on the tenants of cell death. 
83 
 
 The BCL-2 family is implicated in a vast array of diseases, although the best 
characterized BCL-2 family related malady to date is arguably cancer. Great effort has 
been made to generate pharmacological regulators of the BCL-2 family for clinical use as 
single-agent or combination anti-cancer therapies. The most potent and prevalent 
mechanism of apoptosis dysregulation in cancer is overexpression of anti-apoptotic 
family members (Reed, 1997; Wei, 2004). Examples of increased BCL-2 or BCL-xL 
levels in human malignancy include leukemias, lymphomas, and solid tumor epithelial 
malignancies (Letai, 2008). Over-expression of anti-apoptotic proteins has been shown to 
be directly correlated with neoplastic aggressiveness, poor prognosis, and 
chemotherapeutic resistance (Wei, 2004). 
 
 
Experimental Rationale 
 
 An emerging theme in cancer biology is that tumor cells become addicted to high 
levels of anti-apoptotic BCL-2 family proteins in order to maintain survival. This theme 
is in direct agreement with the landmark review “The Hallmarks of Cancer” (Hanahan 
and Weinberg, 2000). One requirement for cancer cells is acquisition of autonomy from 
normal mitogenic signals such that cells continuously divide in an uncontrolled, chaotic 
manner. This is achieved predominantly by constitutive activation of oncogenes such as 
Ras, E1A, Myc, and E2F, which, under normal, non-pathological circumstances trigger 
apoptotic cell death (Evan and Littlewood, 1998; Harrington et al., 1994). Accordingly, 
inhibiting the anti-apoptotic proteins in tumors should induce spontaneous apoptosis of 
the tumor cells or marked sensitization to pro-apoptotic BCL-2 family members which, 
as a result of constitutive oncogenic signaling, induce direct activator BH3-only proteins, 
as seen in chronic lymphocytic leukemia where the neoplastic cells’ anti-apoptotic 
repertoires are “primed” by BIM . Oncogenic priming of tumor cells with direct activator 
BH3-only proteins provides a therapeutic window for the use of small molecule, de-
repressor BH3-only protein mimetics for cancer treatment, as most normal, healthy cells 
do not exhibit direct activator BH3-only protein activation and thus are not primed for 
death. 
 
 Following crystal and NMR structure determination of BCL-xL (Muchmore et al., 
1996a), several drugs were designed to target BCL-xL and the other anti-apoptotic BCL-
2 proteins (e.g., ABT-737) (Oltersdorf et al., 2005). A comparison of several inhibitors of 
the anti-apoptotic BCL-2 proteins showed that only ABT-737 (Abbot Laboratories), 
discovered by obtaining structure-activity relationships by NMR (SAR by NMR) (Hajduk 
et al., 1997), caused cell death in a BAK/BAX-dependent manner (van Delft et al., 2006). 
This small molecule inhibitor neutralizes BCL-2, BCL-xL, and BCL-w with 
subnanomolar affinity and exhibits marked cytotoxic efficacy in combination with 
chemotherapeutics and radiation, although healthy primary cells are not killed (Oltersdorf 
et al., 2005). In pre-clinical studies, ABT-263, an orally bioavailable derivative of ABT-
737, displayed single-agent effectiveness against a variety of tumor types including 
lymphoma and small cell lung cancer (Oltersdorf et al., 2005).  
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Overexpression of MCL-1 has been shown to be a potent mechanism of resistance 
to ABT-737 and ABT-263, as these small molecule BH3-only protein mimetics have a 
binding profile identical to that of BAD, and therefore do not bind MCL-1 (Certo et al., 
2006; Kuwana et al., 2005) (Figure 1.4A). Cancer cells that express high levels of MCL-
1, therefore, are refractory to treatment with the current ABT-737-like compounds. 
 
 The structure of the BCL-xL·PUMABH3 complex we have solved in combination 
with the recently solved structures of MCL-1 (Day et al., 2005), MCL-1·BIMBH3 
(Czabotar et al., 2007), and MCL-1·PUMABH3 (Day et al., 2008) provide a wealth of 
knowledge regarding the intricacies of BH3-domain peptide·anti-apoptotic protein 
interactions. This wealth of knowledge can be used to design novel small molecule BH3 
domain peptide mimetics that could possibly overcome the resistance of some cancer 
cells to ABT-737-like compounds caused by increased MCL-1 expression. 
 
 ABT-737 has been used as a starting small molecule scaffold to develop a pan 
inhibitor of the anti-apoptotic repertoire, although to date these studies have shown no 
success (Fu et al., 2007; Lee et al., 2009). These studies highlight the differences in 
structural properties the anti-apoptotic protein repertoire. These differences are likely to 
be extremely important in developing a pan-inhibitor of the anti-apoptotic repertoire. 
Indeed, it was concluded that flexibility of both the small molecule BH3 mimetic and the 
anti-apoptotic protein significantly contribute to the ability of rationally designed variants 
of ABT-737 derivatized to mimic BIMBH3 to retain binding to BCL-xL (which exhibits a 
high degree of flexibility within the BH3 domain binding groove) but still failed to bind 
MCL-1 (which shows no flexibility within the BH3 binding groove due to the complete 
retention of helicity in helix 3 of the groove) (Lee et al., 2009). 
 
 
Proposal and Experimental Design 
 
 Our structure of the BCL-xL·PUMABH3 complex described above may provide an 
alternative route to accomplishing the goal of developing a novel ABT-737 like 
compound that may not bind MCL-1 but still circumvent the cancer cell resistance 
afforded by MCL-1 overexpression. Using ABT-737 as a model to produce a derivative 
that retains the activity of this small molecule (de-repression of BIM and/or BID primed 
anti-apoptotic proteins) but targets a slightly different area within the BCL-xL BH3-
binding groove to mimic the novel π-stacking interaction seen within our structure would 
result in a BH3 domain peptide mimetic that would also induce BCL-xL dimerization and 
de-repression of an additional direct activator, cytosolic p53. 
 
 For development of such a compound, the principles of SAR by NMR (Hajduk et 
al., 1997) would be employed. Assignments for BCL-xL monomer are available as well 
as assignments for the BCL-xL apo-dimer (Denisov et al., 2007a). First, a library of small 
molecule fragments would be designed to encompass a wealth of small molecule 
fragments containing at least one aromatic group requisite to recapitulate the π-stacking 
feature of W71 in PUMABH3, which we have shown is necessary for PUMA-induced 
BCL-xL dimerization (Figure 3.12 and Figure 3.13) and p53 release from BCL-xL 
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(Figure 3.16). This aromatic group-based small molecule fragment library would be used 
in 2D TROSY NMR experiments wherein the fragments would be added to 15N-labeled 
BCL-xLΔC and the chemical shifts of BCL-xL H113 and residues adjacent to it would be 
monitored for perturbation (Figure 3.28). In the fragment screening process, it would be 
critical to screen the small molecules individually or in small mixtures to avoid fragment 
aggregation resulting from hydrophobic or π-stacking interactions. Fragment solubility 
would also be a concern; therefore the library would need to include aromatic rings that 
are derivatized to increase solubility (e.g., aromatic ring systems with various polar or 
hydrophilic groups attached). 
 
 In addition to screening for small molecule fragments capable of engaging in a π-
stacking interaction with 15N-labeled BCL-xLΔC, it would also be necessary to screen for 
additional small molecule fragments capable of specifically binding within the adjacent 
hydrophobic pockets that surround PUMA I75 and the conserved L79 (formed by BCL-
xL∆C residues V126, L112, L108, F146, F105 and F146, F105, V126, F97, L130 and 
A142, respectively) using NMR as described above (Figure 4.3). In ABT-737, a chlor-
biphenyl moiety engages the PUMA L79 pocket, and could therefore be a high likelihood 
candidate (Lee et al., 2007) (Figure 4.3). Finding small molecule fragments capable of 
packing specifically into these hydrophobic pockets is crucial, as they would provide the 
crucial building blocks to use to link any aromatic small molecule fragment mimetic of 
PUMA W71. 
 
 Positive hits from the initial NMR screen that show chemical shift perturbation in 
the BCl-xL H113 vicinity would then be subjected to a further screen wherein each is 
tested for its ability to induce BCL-xLΔC in native page dimerization assay. Because 
small molecule fragments normally have relatively low affinity for their target protein 
(Sattler et al., 1997), millimolar concentrations of each positive hit fragment would be 
added to a small volume of approximately 25 μM BCL-xLΔC, incubated at 30 °C for one 
hour, and the resulting treatments would be screened for BCL-xLΔC dimerization by 
native PAGE.  
 
Fragments that induce BCL-xLΔC dimerization would then be linked using 
synthetic chemistry approaches to connect small molecule fragments found to engage 
PUMA I75 and L79 within the BH3 binding groove. The approach to linking these small 
fragments would be based on the surface topology characteristics between these binding 
pockets so as to avoid issues such as steric clashes between the compound and BCL-xL 
side chains as well as attempting to avoid charge-charge incompatibility between the 
backbone linker scaffold and BCL-xL. Linker scaffolds should also afford a degree of 
flexibility in order for the final PUMA small molecule mimetic to engage the BH3 
domain binding groove in the manner seen for PUMABH3, which folds upon binding and 
therefore results in optimal positioning of peptide·protein interactions within the BCL-xL 
binding groove. Additionally, BCL-xL refolds to accommodate the incoming peptide or  
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Figure 4.3 Target Areas of BCL-xL Used to Screen for a Novel Small Molecule 
PUMABH3 Mimetic. 
Surface representation of one side of the BCL-xL PUMABH3 dimer complex is shown for 
clarity. Helix 3 is pink and helix four is blue. The three primary small fragment target 
sites for structure activity relationship by nuclear magnetic resonance (SAR by NMR) are 
adjeacent to the PUMABH3 side chains in yellow. ABT-737 (green) was superposed using 
the BCL-xLΔLΔC·ABT-737 structure (PDB ID:2YXJ). PUMA L79 and the chlor-
biphenyl moiety of ABT-737 overlap and occupy the same hydrophobic binding pocket. 
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BH3 mimetic compound (specifically helix 3 described above) (Lee et al., 2009). If a 
PUMA BH3 mimetic capable of inducing BCL-xL dimerization is successfully 
accomplished, the compound would likely need to undergo further chemical 
modifications in order modulate its solubility and pharmacokinetics to ensure it is able to 
not only make itto the cancer cells (which can be impeded by binding of compounds to 
serum proteins which reduces bioavailability) as well as penetrate the tumor cells 
(Oltersdorf et al., 2005).  
 
A PUMA mimetic would likely show the highest efficacy in cancer types that 
retain the ability to upregulate wild type p53. In this scenario, cancer cells primed for 
death by the direct activator BH3-only proteins BID and/or BIM and/or by cytosolic p53 
(induced by continuous oncogenic signaling as described above), would undergo MOMP 
and cell death via de-repression by the PUMA BH3 mimetic. Cytosolic p53 has been 
found in numerous tumor cell lines bound to BCL-xL and engages MOMP in a PUMA-
dependent manner (Speidel et al., 2006). A BH3 mimetic able to de-repress not only two 
but three different direct activator proteins should increase the likelihood of cancer cell 
death. 
 
It is interesting to speculate that such a novel BH3 mimetic could indeed show 
binding to MCL-1. Unlike ABT-737 which engages the BH3 binding groove near the 
proteins C-terminus (Lee et al., 2007), a PUMA mimetic designed as described above 
would target the opposite end of the binding groove. It is possible that targeting this 
region of MCL-1 might allow higher affinity binding since the hydrophobic pockets used 
to engage BH3-only proteins are deeper within this region, whereas the pockets targeted 
by ABT-737 are much shallower (Day et al., 2005) and cause steric clash. If the PUMA 
mimetic does show appreciable binding to MCL-1, cancers resistant to ABT-737-like 
compounds would likely be susceptible to the novel PUMA mimetic, independent of its 
ability to de-repress cytosolic p53. 
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Table A.1 Oligonucleotide Primers for Site-directed Mutagenesis. 
 
Protein Oligonucleotide 
BCL-xLΔC E7C 
5′ ATATGTCTCAGAGCAACCGGTGCCTGGTGGTTGACTTTCTCTC 3′ 
5′ TATACAGAGTCTCGTTGGCCACGGACCACCAACTGAAAGAGAG 3′ 
BCL-xLΔC H113A 
5′ CTGACATCCCAGCTCGCCATCACCCCAGGGAC 3′ 
5′ GACTGTAGGGTCGAGCGGTAGTGGGGTCCCTG 3′ 
BCL-xLΔC V135C 
5′ CCGGGATGGGTGCAACTGGGGTCGCATTGTGGC 3′ 
5′ GGCCCTACCCACGTTGACCCCAGCGTAACACCG 3′ 
BCL-xLΔC N175C 
5′ GGATGGCCACTTACCTGTGTGACCACCTAGAGCCTT 3′ 
5′ CCTACCGGTGAATGGACACACTGGTGGATCTCGGAA 3′ 
BCL-xLΔC W181C 
5′ GACCACCTAGAGCCTTGCATCCAGGAGAACGGC 3′ 
5′ CTGGTGGATCTCGGAACGTAGGTCCTCTTGCCG 3′ 
PUMA W71A 
5′ CGCGGGGAGGAGGAACAGGCGGCCCGGGAGATC 3′ 
5′ GATCTCCCGGGCCGCCTGTTCCTCCTCCCCGCG 3′ 
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Table A.2 Details of Recombinant Protein Expression Vectors. 
 
Vector Name Antibiotic Resistance Fusion Tag Cleavage Method Origin 
BAX-pTB1 Amp Intein (N) 50 mM DTT Green Lab 
BCL-xLΔC-pET28 Kan 6His (N) Thrombin C.G. Park 
BCL-xLΔLΔC-pET21 Amp 6His (C) None Wagner Lab 
BCL-xLΔC E7C-pET28 Kan 6His (N) Thrombin J. Fisher 
BCL-xLΔC H113A-pET28 Kan 6His (N) Thrombin J. Fisher 
BCL-xLΔC N175C-pET28 Kan 6His (N) Thrombin J. Fisher 
BCL-xLΔC V135C,W181C-pET28 Kan 6His (N) Thrombin J. Fisher 
PUMA beta-pET30 Kan 6His (N) Thrombin Eldering Lab 
PUMA beta W71A-pET30 Kan 6His (N) Thrombin J. Fisher 
PUMA betaN-pET30 Kan 6His (N) Thrombin C.G. Park 
PUMA betaC-pET30 Kan 6His (N) Thrombin C.G. Park 
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Figure A.1 Reversed Phase C4 HPLC Chromatogram of PUMA. 
Shown are the two primary peaks seen during HPLC purification of PUMA. The first 
peak is discarded and the second peak containing active PUJMA protein is subsequently 
flash frozen and lyophilized. The blue line indicates the linear acetonitrile gradient used 
over the course of one hour. The linear acetonitrile gradient was set to increase 1 % each 
minute for a total of one hour.
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Table A.3 Example of Raw Fluorescence Data Used to Solve for Kd by Non-
linear Regression. 
 
[BCL-xL] (M) % Bound % Bound % Bound 
0.00 1.174e-006 0.000000 0.000000 
2.460000e-011 0.0007622 0.003850402 0.01752863 
4.910000e-011 0.0066133 0.01733965 0.0292946 
2.510000e-009 0.2314529 0.183359 0.2717325 
4.960000e-009 0.4408391 0.3601685 0.4247327 
7.420000e-009 0.5570283 0.5194997 0.5024741 
9.880000e-009 0.6227446 0.6063511 0.5401847 
1.230000e-008 0.6573826 0.6383788 0.5716024 
1.480000e-008 0.6843936 0.7007385 0.594900 
1.720000e-008 0.7110994 0.7194165 0.6251428 
4.180000e-008 0.8624737 0.8874713 0.7938736 
6.640000e-008 0.9085243 0.9249331 0.9243155 
1.890000e-007 1.000000 1.000000 1.000000 
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Figure A.2 Determining the Kd and -ΔΔG Value for Fluorescein-labeled Wild 
Type PUMABH3. 
Non-linear regression plot used to determine the Kd for wild type PUMABH3 (upper 
panel). The results and corresponding fitting statistics for a set of triplicate data obtained 
for wild type PUMABH3 (lower panel). ΔG was determined using the equation:  
ΔG = -(R)(T)ln[(1/Kd)]. 
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Table A.4 Thermodynamic Parameters for BCL-xL Binding to Various BH3 Domain Peptides. 
 
Interaction Kd (nM) ΔGa (kcal·mol-1) ΔH (kcal·mol-1) -TΔS (kcal·mol-1) 
     
BCL-xLΔC·BADBH3 0.2 ± 0.3 -13.2 -13.8 -0.53 
     
BCL-xLΔC·BAKBH3 27.5 ± 30 -10.31 -7.96 2.35 
     
BCL-xLΔC·BAXBH3 111.90 ± 75 -9.47 -8.88 0.60 
     
BCL-xLΔC·BIDBH3 10.1 ± 15 -10.9 -8.16 2.74 
     
BCL-xLΔC·BIMBH3 0.50 ± 6.6 -12.7 -10.6 2.07 
     
BCL-xLΔC HRKBH3 28.8 ± 35 -10.3 -13.0 -2.70 
     
BCL-xLΔC·NoxaBH3 ND ND ND ND 
     
BCL-xLΔC·PUMABH3 2.93 ± 1.7 -23.9 -16.34 7.57 
     
Notes: In all of the above experiment, the binding stoichiometry was determined by fitting the data to a 1:1 binding model. Errors 
represent the standard deviations from the mean of at least two independent experiments. 
a Calculated using the equation ΔG = -RT ln(Ka). 
b Calculated using the equation ΔG =ΔH-tΔS. 
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APPENDIX B.    RECOMBINANT PROTEIN SEQUENCES 
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BCL-xLΔC 
 
GSHMSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAIN
GNPSWHLADSPAVNGATAHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFS
DLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQ
VLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQER 
 
BCL-xLΔLΔC  
 
MSMAMSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSA
INGNPSWHLADSPAVNGATAHSSSLDAREVIPMAAVKQALREAGDEFELRYRRA
FSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEM
QVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERLE
HHHHHH 
 
BCL-xLΔC E7C 
 
GSHMSQSNRCLVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAI
NGNPSWHLADSPAVNGATAHSSSLDAREVIPMAAVKQALREAGDEFELRYRRA
FSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEM
QVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQER 
 
BCL-xLΔC N175C 
 
GSHMSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAIN
GNPSWHLADSPAVNGATAHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFS
DLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQ
VLVSRIAAWMATYLCDHLEPWIQENGGWDTFVELYGNNAAAESRKGQER 
 
BCL-xLΔC V135C,W181C 
 
GSHMSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAIN
GNPSWHLADSPAVNGATAHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFS
DLTSQLHITPGTAYQSFEQVVNELFRDGCNWGRIVAFFSFGGALCVESVDKEMQ
VLVSRIAAWMATYLNDHLEPCIQENGGWDTFVELYGNNAAAESRKGQER 
 
GST-BFL-1ΔC 
 
GPPEFTMTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVE
KNLKSCLDNVNVVSVDTARTLFNQVMEKEFEDGIINWGRIVTIFAFEGILIKKLLR
QQIAPDVDTYKEISYFVAEFIMNNTGEWIRQNGGWENGFVKKF  
 
MCL-1ΔNΔC 
 
MHHHHHHEDDLYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVG
DGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFG
110 
 
AFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLE
GGIRNVLLAFAGVAGVGAGLAYLIR 
 
PUMA beta  
 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMK 
FGMGSAQACPCQVPRAASTTWVPCQICGPQPSLSLAEQHLESPVPSAP 
GALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNAQYERRRQEE 
QQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN 
 
PUMA betaW71A  
 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMKFGMGS
AQACPCQVPRAASTTWVPCQICGPQPSLSLAEQHLESPVPSAPGALAGGPTQAAP
GVRGEEEQAAREIGAQLRRMADDLNAQYERRRQEEQQRHRPSPWRVLYNLIMG
LLPLPRGHRAPEMEPN 
 
PUMAC 
 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMAK 
FGMGSAQACPCQVPRAASTTWVPCQICGPQPSLSLAEQHLESPVPSAP 
GALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNAQYERRRQEE 
QQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN 
 
PUMAN 
 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMK 
FGMGSAQACPCQVPRAASTTWVPCQICGPQPSLSLAEQHLESPVPSAP 
GALAGGPTQAAPGVRGE
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APPENDIX C.    BUFFERS 
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Nickel Affinity Binding Buffer (Lysis Buffer) 
20 mM Tris, pH 8.0 
5 mM imidazole 
500 mM NaCl 
Two EDTA-free protease inhibitor tablets (Roche) per 100 ml buffer 
 
Nickel Elution Buffer 
20 mM Tris, pH 8.0 
500 mM imidazole 
500 mM NaCl 
 
GST Binding Buffer (Lysis Buffer) 
140 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
Two protease inhibitor tablets (Roche) per 100 ml buffer 
 
GST Elution Buffer 
50 mM Tris, pH 8.0 
10 mM reduced glutathione 
 
Anion Exchange Binding Buffer 
50 mM Tris, pH 80=.0 
10 mM NaCl 
 
Anion Exchange Elution Buffer 
50 mM Tris, pH 8.0 
1.0 M NaCl 
 
Gel Filtration Buffer 
50 mM Tris, pH 8.0 
300 mM NaCl 
 
PUMA NMR Buffer 
20 mM deuterated Tris, pH 7.1 
150 mM NaCl 
5 mM deuterated DTT 
 
BCL-xL NMR Buffer 
20 mM sodium phosphate, pH 7.0 
3.0 mM DTT 
0.5 mM EDTA 
 
CD Buffer 
20 mM potassium phosphate, pH 7.0 
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HPLC Column Binding Buffer 
0.1 % TFA (V/V) in H2O 
 
HPLC Column Elution Buffer 
0.1 % TFA (V/V) in acetonitrile 
 
Natve PAGE Running Buffer 
25 mM Tris, pH 8.3 
192 mM glycine 
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